Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol By Pooria Nakhaei, Ria Margiana, Dmitry O Bokov, Walid Kamal Abdelbasset, Mohammad Amin Jadidi Kouhbanani, Rajender S Varma, Faroogh Marofi, Mostafa Jarahian, Nasrin Beheshtkhoo Published in: Frontiers in Bioengineering and Biotechnology DOI: 10.3389/fbioe.2021.705886 ABSTRACT Abstract Liposomes are essentially a subtype of nanoparticles comprising a hydrophobic tail and a hydrophilic head constituting a phospholipid membrane. The spherical or multilayered spherical structures of liposomes are highly rich in lipid contents with numerous criteria for their classification, including structural features, structural parameters, and size, synthesis methods, preparation, and drug loading. Despite various liposomal applications, such as drug, vaccine/gene delivery, biosensors fabrication, diagnosis, and food products applications, their use encounters many limitations due to physico-chemical instability as their stability is vigorously affected by the constituting ingredients wherein cholesterol performs a vital role in the stability of the liposomal membrane. It has well established that cholesterol exerts its impact by controlling fluidity, permeability, membrane strength, elasticity and stiffness, transition temperature (Tm), drug retention, phospholipid packing, and plasma stability. Although the undetermined optimum amount of cholesterol for preparing a stable and controlled release vehicle has been the downside, but researchers are still focused on cholesterol as a promising material for the stability of liposomes necessitating explanation for the stability promotion of liposomes. Herein, the prior art pertaining to the liposomal appliances, especially for drug delivery in cancer therapy, and their stability emphasizing the roles of cholesterol. Keywords: liposome, lipids, compounds, cholesterol, stability INTRODUCTION Increasing advances in nanotechnology and nanoscience have raised great hopes in the field of biomedicine. Due to their unique, multifaceted and flexible properties, nanomaterials circumvents many challenges in diverse fields of medicine, including health, diagnosis, and treatment (Liu et al., 2020; Naskar and Kim, 2021), nanoliposomes being one of the most widely used nanoparticles in biomedicine. Liposomes are lipid bilayer spherical membranes that provide both hydrophilic and hydrophobic environments. Adjustability, flexibility, variety of ingredients, ease of functionalization, tunability of the number of layers/sizes, biocompatibility, and biodegradability have turned liposomes into incredible structures in medicine, especially drug delivery (Aguilar-Pérez et al., 2020; Trucillo et al., 2020; Kashapov et al., 2021), most notable use of these structures being in cosmetics and drug delivery. Consequently, various liposome-based products have been commercialized to date, with the approval from United States Food and Drug Administration (FDA) (Yuba, 2020; Barenholz, 2021). Liposomes, a type of lipid-based nanoparticle, have a great assortment each of which in turn offers unique properties. However, there are still barriers and challenges related to lipid nanoparticles, the most critical being their stability (Yu et al., 2021). In the present review, an attempt has been made to comprehensively deliberate liposomes in terms of structure, function, and stability starting initially with an introduction to lipid structures. Lipid Nanoparticles Lipid molecules are one of the crucial elements of life and lipid-based nanoparticles comprise a broad range according to their application, components, shape, and fabrication methods; they possess numerous advantages over polymeric-based nanoparticles. Besides topical usage, agent delivery is ascribed to as a significant application of lipid-based nanoparticles. Being a physiological analog to the cellular membrane, liposomes have superior biocompatibility compared to polymeric-based nanoparticles, leading to a more acceptable biomedical application choices (Müller et al., 2000). As highly adaptable nanoparticles, lipidic nanoparticles can be deployed for a wide varieties of delivery with a bit of condescension. Liposomes and niosomes, as the phospholipid and amphipathic lipids constituents, respectively, are the most known lipid-based formulation. According to previous studies, liposomes could be engineered purposefully with favorable parameters. However, kinetic stability is the primary limitation of vesicular lipid-based nanoparticles, including liposomes (Battaglia and Ugazio, 2019). The most applicable lipid-based nanoparticles are presented in Table 1. [Table: Lipid-based structures.] Liposome Structure Liposome structure has been initially described by the British hematologist, Alec D Bangham in 1961. From the terminology point of view, liposome consists of “Lipos” and “Soma,” attributed to fat and body, respectively. The cell membrane’s bilayer lipid structure has been determined using electron microscope images, proving their unmistakable resemblance to plasmalemma (Dua et al., 2012; Hashemzadeh et al., 2020a). Liposomes were recruited as a drug carrier for the first time in the early 1990s. It has since been concluded that the low percentages inclusion of lipid-bonded polymers (called polymer-lipids) in liposomes’ structure could increase blood circulation in vivo. Structurally, liposomes are concentric bleeder vesicles in which a membranous lipid bilayer surrounds an aqueous volume. Typically, the bilayer lipid membrane comprise phospholipids containing a hydrophobic tail and a hydrophilic head (Rovira-Bru et al., 2002). According to the phospholipid’s properties, the final structure represents an amphiphilic feature (Dua et al., 2012). Due to the unique structure, both natural and synthetic phospholipids-based liposomes are considered vesicles or drug-carrying systems. The spherical or multilayered spherical design of the fabricated liposomes is highly reliant on the amount and the kind of lipid components. According to a concentric form, the bilayer lipid formation arrangement constitutes an equal number of water chambers (Chetoni et al., 2004; Choi and Maibach, 2005; Pavelić et al., 2005). In view of the utmost similarity to the cell membrane, the liposomes have been described as an appropriate membrane model to reveal the fundamental nature of cell membranes with assorted appliances (Wong et al., 2001; Laouini et al., 2012). The self-assembly of diacyl-chain phospholipids in aqueous solutions can form spherical bilayer structures referred to as liposomes. Because of encapsulating an extensive aqueous environment, liposomal structures can load almost any type of hydrophilic molecules (Lebègue et al., 2015; Vakili-Ghartavol et al., 2020; Wu et al., 2021). Liposome’s internal hydrophilic part can protect loaded drugs from the host body’s destructive factors that ultimately minimize the unwanted side effects. Besides the internal aqueous environment, hydrophobic substances can also be embedded between the lipid membranes or adsorb on the liposome surface (Xu et al., 2007; Silverman et al., 2013; Chen et al., 2014; Eloy et al., 2014; Jain et al., 2014). The essential liposome-like structures are presented in Table 2. [Table: Liposome-like structures.] The Packing Parameter As described, liposomes are lipid-based structures that constitute one or more bilayer phospholipids which can encapsulate aqueous media. Liposome formation begins by dispersing phospholipids in water, leading to interactions between phospholipids and water (Anwekar et al., 2011), PP being a critical criterion determining the formation of liposome. PP is described as the ratio between the cross-section of the amphiphile hydrophobic part (hydrocarbon chains of phospholipids or the hydrocarbon rings of sterols) and the cross-section of the hydrophilic part (the amphiphile head group). Liposome-forming lipids are considered amphiphilic structures with a PP of 0.74–1.0. In this regard, HSPC (PP: 0.8) and DSPE–PEG (PP: 0.487) have been addressed as liposome and non-liposome forming lipids, respectively. For DSPE-PEG, the low PP implied the presence of an extensive polar head group due to the large (45 mer) polyethylene glycol (PEG) moiety that prevents liposome-structure formation. The head group in this molecule is highly flexible (Nagarajan, 2002; Garbuzenko et al., 2005; Barenholz, 2016; Maritim et al., 2021). The most common phospholipids and cholesterol deployed to prepare liposomes with respect to their transition temperature (Tm) and molecular weights are presented in Table 3. [Table: The common compounds deployed to prepare liposomes.] TYPES OF LIPOSOMES Liposomes are highly versatile compounds and they can be fabricated with various combinations, their diversity and properties vary in structure, size, shape, and surface properties. One of the classification types of liposomes is founded on their size and amount of layers, for example, unilamellar and multilamellar liposomes. They can be subdivided into four main categories based on structural parameters: multilamellar liposomes/vesicles (MLV), oligolamellar vesicles (OLV), multilamellar liposomes/vesicles (MVV), and unilamellar vesicles (ULV). Furthermore, the ULV can be divided into giant unilamellar liposomes/vesicles (GUV) groups, large unilamellar liposomes/vesicles (LUV), medium unilamellar vesicles (MUL), and small unilamellar liposomes/vesicles (SUV), and based on size (Walde and Ichikawa, 2001; Gabriëls and Plaizier-Vercammen, 2003; Wagner et al., 2006; Drulis-Kawa and Dorotkiewicz-Jach, 2010; Baykal-Caglar et al., 2012; Garg and K. Goyal, 2014). Despite the aforementioned classification of various liposomes, many liposome characteristics cannot be deduced, including synthesis techniques or their applications. Since the introduction of liposomes as lipid-carrying structures, many methods have been proposed for their fabrication. Each has some advantages and disadvantages that can be exploited depending on the practical function. The process of liposome making strongly affects the final properties, so special attention should be paid to the construction method. Liposomes are referred to as a very miscellaneous structure in terms of their charge and size, the ultimate size and electrical charge of the fabricated liposome being highly reliant on the manufacturing method and the types of phospholipid deployed. In this regard, liposomes synthesis methods can be categorized as dehydration and rehydration (DRV), reverse phase evaporation (REV), particularly for SUL, OLV, and MLV liposomes, vesicles prepared by extrusion technique (VET), and frozen and thawed (FAT) for MLV preparation (Zhang and Pawelchak, 2000; Scott and Jones, 2001; Xia and Xu, 2005; Zaru et al., 2007; Akbarzadeh et al., 2013; Pradhan et al., 2015). Assorted liposome types, according to the fabrication methods, are presented in Table 4. [Table: Liposome classification based on the synthesis method.] Regarding the production of liposome, in addition to the fabrication method, drug loading should also be considered. In general, drug loading is performed via two standard procedures, passive and active loading, which affects the amount and quality of the loaded drug and some extent on the liposome properties. In the active loading method, known as the remote loading method, the drug molecules are loaded into the fabricated liposome. The pH gradient and electrical potential difference across the liposomal membrane are the most known underlying mechanisms dictating the active drug loading (Figure 1). The active loading method has provided various advantages over passive loading methods, including high efficiency and loading capacity, decreasing the loaded drug’s leakage, and reducing the drug’s shrinking during storage. Another outstanding feature of this method is the possibility of drug loading after carrier formation due to the use of the flexibility of constitutive lipid. It is also possible to prevent the degradation of the biologically active compounds during the preparative process (Barratt, 2003; Anwekar et al., 2011; Agrawal et al., 2012; Burton et al., 2015). [Figure: The active and passive drug loading on the liposomes.] It has been well known that liposome characteristics are highly dependent on lipid composition. Surface charge, particle size, and the preparation method are among the most outstanding influenced features by lipid combination. Besides, the effective properties of bilayer structure, including rigidity, fluidity, and electrical charge, can be determined through bilayer component selection. In this regard, natural-based liposomes fabricated from unsaturated phosphatidylcholine species, including egg or soybean phosphatidylcholine, have provided bilayer structures with highly permeable and low stable properties. However, saturated-phospholipids-based liposomes such as dipalmitoyl phosphatidylcholine lead to rigid and almost impermeable bilayer structures (AllenLiposomes, 1997; Sahoo and Labhasetwar, 2003). The most common liposomal system, in terms of its composition constituent, are presented in Table 5. [Table: liposome classification according to composition constituents.] APPLICATION OF LIPOSOMES As highly versatile nanoparticles, liposomes have been considered for many biomedical applications (Figure 2). Liposome as cholesterol and natural-non-toxic phospholipids-based spherical shape vesicles has provided many biomedical opportunities, especially for drug delivery ascribed to their biocompatibility, appropriate size, and suitable hydrophobic and hydrophilic character. Besides, the cosmetics industry has been vigorously affected by liposome formulations as they proposed many unique properties for drug carriers (Figueroa-Robles et al., 2020; Matole et al., 2020). On the other hand, the great potential application of liposomes should not be underestimated in the food and farming industries. Numerous studies have been conducting regarding liposome encapsulation to develop appropriate delivery systems to entrap unstable compounds. The ensnared invertebrate ingredients such as antimicrobials, antioxidants, hydrophobic, and hydrophilic compounds in liposome particles could be used to targeted delivery and prevent composition and functionality disruption (Benech et al., 2002; Shehata et al., 2008; Atrooz, 2011). [Figure: Diverse biomedical applications of liposome-based structure.] The nanoliposome is a favorable particle to develop cancer drug delivery systems due to its unique properties, including biocompatibility, biodegradability, and hydrophilic and lipophilic drug loading capability. Liposome-based structures have owned the most commercial delivery systems worldwide. There is various ongoing research regarding improvement drug toxicity and specific targeting with liposomes (Akbarzadeh et al., 2013). In view of the admirable properties mentioned for liposomes, it has been extensively studied in drug delivery to cancerous and tumor tissues via two main approaches in terms of design to target tumor tissues: passive targeting and active targeting (Figure 3). Passive targeting is reliant on the physiological characteristics of the tumor and the size of the nanoparticles. Cancer cells overexpress vascular endothelial growth factor (VEGF) due to their very high metabolism, which leads to excessive angiogenesis in tumor tissue. The vascular pores in the tumor tissue are larger than normal tissue, and the appropriate size of the liposomes enable them to circulate for a longer time in the circulatory system, so the anti-cancer drug nanosystem could target the tumor tissue (Zhu et al., 2017; Jeon et al., 2020; Liu et al., 2021). In addition, after the drug delivery system enters the cancerous tissue due to defects in the lymphatic system, the retention time of nanoparticles increases, which is not possible for the small drug molecules (Attia et al., 2019). In this method, the nanosystem is also coated with a biocompatible PEG polymer, which causes the escape of the reticuloendothelial (RES) system and increases the circulation time in the circulatory system; effect of PEG is through shielding liposomes from opsonization (Suk et al., 2016; Nunes et al., 2019). [Figure: Passive targeting and active targeting. Liposomes can be surface functionalized to dedicate stealth through PEGylation and to meliorate receptor-mediated endocytosis by utilizing targeting ligands such as antibodies, peptides, proteins, carbohydrates, Aptamer, and various other small molecules. PEGylation prolongs liposomal circulation half-life in vivo. Types of drugs based on whether they are hydrophobic or hydrophilic can be encapsulated into the aqueous lumen, incorporated into the lipid bilayer, or conjugated to the liposome surface.] Despite the relatively good performance of passive targeting in increasing drug delivery to cancerous tissues, the optimum amount may still not reach the target tissue, or the drug may leak into normal tissues. Hence, researchers are using the active targeting method to enhance drug delivery to the target tissue. The basis of this method can be attributed to the functionalization of the liposome surface. Cancer cells need more nutrients because of their distinct metabolism. Therefore, some surface receptors are overexpressed on the surface of these cells. Targeted drug delivery to the cancerous tissue can be performed using this feature through specifically functionalizing liposome surface (Dana et al., 2020; Montaseri et al., 2020; Raj et al., 2021). A comprehensive overview of liposomes’ applications in biomedicine is summarized in Table 6 according to the type of liposomes used. [Table: The use of liposome in biomedical applications.] Advantages and Disadvantages of Liposomes Like any other carrier, liposomes have provided some advantages and disadvantages, too. The benefits of liposomes have been mentioned briefly in this text. As amphiphilic and non-ionic structures particle, liposomes offer an exceptional opportunity to deliver both water and lipid-soluble drugs. This feature has a significant priority in the pharmaceutical industry to develop new formulations (Abdelkader et al., 2014; Joshi et al., 2016). On the other hand, their inimitable structure frame enables researchers to fabricate both sustained and targeted drug delivery systems through controlling permeability, rigidity, size, and surface functionalization (Daraee et al., 2016; Jain and Jain, 2016). Although liposomes can be administered through different routes, they are composed of biocompatible ingredients (Mansoori et al., 2012). One of the main limitations of drug distribution systems is the importance of biodegradable drug transport, which can be overcome through liposomal delivery that prevents drug oxidation (Manconi et al., 2016). It has been reported that liposomes can promote drug pharmacokinetics by eliminating and circulation life (Bhatt et al., 2018). Despite all advantages, liposome-based structures have some limitation that prevents their widespread clinical use. The most significant obstacle is attributed to their physical and chemical stabilities (Bakker-Woudenberg, 2002). Among other essential impediments, low solubility in aqueous solutions (Li et al., 2019), short half-life time in body environment (Kshirsagar et al., 2005), high production cost (Noble et al., 2014), challenges in various tissue targeting due to the relatively large size of liposomes may cause (Santos et al., 2005), leakage and fusion of the loaded drugs (Joly et al., 2011), phospholipids oxidation and hydrolysis (Jain and Jain, 2016), rapidly detection by RES system (Daraee et al., 2016), and allergic reactions to some liposomal compounds (Mansoori et al., 2012), can be mentioned. LIPOSOME STABILITY One of the most critical challenges in liposome application is attributed to the relative instability in aqueous dispersions. The physical and chemical instability of liposomes can lead to unwanted side effects and efficacy reduction (Scrimgeour et al., 2005; Toh and Chiu, 2013); oxidation and hydrolysis are two primary mechanisms in the degradation of liposomes that cause chemical instability (Carlson et al., 2006; Jung et al., 2006; Frenzel and Steffen-Heins, 2015). The oxidation process is very probable due to free radicals in fatty acids as an intrinsic compound where unsaturated fatty acids are more susceptible than the saturated fatty acids to this mechanism (Anderson and Omri, 2004; Tan et al., 2016). In the presence of acid- or baseـ catalyst, this process can occur either at the 1-acyl or at the 2-acyl position, which subsequently leads to lysophospholipids through free fatty acids generation, eventually undergoing hydrolysis to free fatty acids and creating phosphoglycerols (Patel and Panda, 2012; Frenzel and Steffen-Heins, 2015). The combination of membrane bilayers, aggregation, reduced retaining of encapsulated materials, and alteration can be mentioned as the causes for physical instability in liposomes (Karmali and Chaudhuri, 2007; Shim et al., 2013; Rahdar et al., 2019). The administrated liposome fate and stability can be strongly affected by liposomes’ physicochemical characteristics, including bilayer membrane composition, size, rigidity, and charge (Portet and Dimova, 2010; Ghanbarzadeh et al., 2013; Ib and Corredig, 2013). The surface charge of liposomes can be positive, negative, or without electrical charge based on functional groups on liposomes’ surface at the environmental pH. As such, net-charge liposomes have represented the highest tendency to accumulate in the target tissue following systematic administration due to the reticuloendothelial system’s low clearance. On the other hand, cationic liposomes are often used to transport negatively charged nucleic acids (Xia and Xu, 2005; El-Samaligy et al., 2006a; Demetzos, 2008; Fujisawa et al., 2012). The methods used to prepare liposomes significantly affect physical properties, such as the coating of active compounds’ size and efficiency. Various phenomena such as aggregation and mixing can affect material properties, such as particle size and particle size distribution, attributed to the accumulation of liposomal particles. It has been reported that particle size reduction can be used for achieving bioactive compounds with optimal bioavailability due to increasing specific surface area (Campbell et al., 2001; Miao et al., 2002; Ulrich, 2002; Silva et al., 2011). The smaller the liposomal size, easier it is to cross the membrane, but it can affect the liposomal properties, including decreasing the amount and efficiency of drug loading and reducing liposome stability by increasing the surface energy. The smaller the particle size distribution, the more uniform is the liposomes’ size and the more similar would be the products’ overall characteristics (Marsh, 2001; Yamauchi et al., 2007; Drin et al., 2008). Another critical factor affecting the stability of liposomes is referred to lipid composition. Studies have shown that controlling solute retention by liposomes and circulation half-life can be strongly affected by liposomal membrane fluidity and composition manipulation. One of the most critical barriers to prevent the transfer of liposomal drugs from the bench scale to the pharmaceutical market is their physical and chemical instability during production and storing. The mechanically robust and well-filled bilayers diminish the oxidizing and hydrolyzing agents that eventually improve the structure stability through size distribution (Kunzelmann-Marche et al., 2002; Liu and Krieger, 2002; López-Revuelta et al., 2006; Giulimondi et al., 2019); composition of the bilayer membrane is one of the influential and essential factors in liposome stability. The lipid selection during liposome fabrication should be commensurate with the carrier’s composition (Jiménez-Escrig and Sánchez-Muniz, 2000; Scheffer et al., 2005; Zhao et al., 2015; Ricci et al., 2016). The Effect of Cholesterol on Liposome Membrane Stability Cholesterol is an organic sterol molecule with amphiphilic nature. Structurally, this molecule has a hydroxyl group that can form hydrogen bonds with phospholipids and bulky steroid ring with a flexible carbohydrate. Cholesterol is a 27-carbon molecule found in the eukaryotic cell membrane and its concentration in the cell membrane is about 30–50 mol% of the entire lipid compounds. Various vital roles have been attributed to cholesterol, including membrane permeability regulation, elasticity and stiffness, and membrane strength. Cholesterol is the most used sterol in the formulation of liposomes which can prevent liposome aggregation and improve the liposomal membrane’s stability (Jiménez-Escrig and Sánchez-Muniz, 2000; Scheffer et al., 2005; Sun et al., 2007; Ricci et al., 2016; Trucillo et al., 2017). In view of the spherical 3-D structure, liposomes have shown more realistic fluidity and cell membrane mobility than lipid monolayers. Sterols, such as ergosterol, stigmasterol, lanosterol, β-sitosterol and cholesterol, have been added to liposomes to modulate membrane fluidity and improve the stability of the phospholipids bilayer and decrease permeation of the encapsulated active compounds. The sterol molecule is located inside the phospholipid’s bilayer. The sterol carbohydrate tail at C17 intermingles with the hydrophobic fatty acyl chains, while the sterol hydroxyl group attaches to the hydrophilic head group of phospholipids (Socaciu et al., 2000; Sodt et al., 2015; Zhao et al., 2015; Giulimondi et al., 2019). Cholesterol plays a vital role in the liposome’s composition. It is one of the most critical structural components in the mammalian cell plasma membrane. It has been proven that the fluidity and permeability of the artificial vesicle are strongly affected by cholesterol through hydrogen binding to fatty acids that eventually lead to increasing the cohesiveness and mechanical strength. Cholesterol is a critical regulator of lipid bilayer dynamics, and it is essential for the normal functioning of the cells. The reduction of passive permeability to small molecules results from cholesterol interaction with membrane phospholipids, increasing the membrane cohesion. According to experimental studies, cholesterol adding to liposome bilayers can prevent lipid exchange that can be counted as an additional stabilizing effect (Sun et al., 2007; Ricci et al., 2016; Trucillo et al., 2017). The Relationship Between Cholesterol and Transition Temperature Another significant factor in the arrangement of bilayers in the liposome is the degree of saturation in phospholipids and the chain length. The presence of sterols such as cholesterol, β-sitosterol, and related plant sterols can lead to the pre-transition temperature peak’s disappearance. The gel-to-liquid crystalline phase Tm has been reported to decrease by addition of the sterols. It can be stated that the orientation of cholesterol in the lipid bilayer has a determinative effect on the reduction of head group accumulation. In the low Tm, cholesterol leads to the crystallization of the hydrocarbon chains into the inflexible crystalline gel phase. While in the high Tm, the rigid cholesterol molecule can limit the movement of the hydrocarbon chains. It can be concluded that, by increasing the sterol concentration, decreases the enthalpy of the main phase transition (Silva et al., 2011; Wu et al., 2012; Ricci et al., 2016). For example, in the case of the PC molecule, it has been stated that cholesterol at concentrations of more than 25% leads to an order-liquid phase, which is essential for the mobility of membrane compounds; inferred that cholesterol at high concentrations causes the decouples of positional and conformational degrees of freedom of phospholipid molecules. On the other hand, at low cholesterol concentrations below 10%, its effect on the bilayer phospholipid is very different; only a slight decrease in the Tm, the main phase transfer occurs. This means that cholesterol at low concentrations cannot disrupt the crystalline order, nor can it ultimately induce the acyl chains in the liquid phase. Cholesterol, therefore, functions as a surfactant molecule, which causes the formation of lipid domains thus increasing the dynamic membrane heterogeneity (Trandum et al., 2000; Pinilla et al., 2020). The Role of Cholesterol in Retention of Drugs and Modulation of Phospholipid Packing The cholesterol content has a critical role in drug retention as it implies its effect by raising the phospholipid packing, leading to bilayer permeability reduction to non-electrolytic and dielectrolysis solvents (Dos Santos et al., 2002; Johnston et al., 2007). It is believed that the underlying mechanism in a biological milieu may be related to the phospholipid and high-density lipoproteins exchange of the low-cholesterol or no-cholesterol content liposomes while in cholesterol-encompassing liposomes, the phospholipid motility has been limited that prevents lipoproteins loss (Kunzelmann-Marche et al., 2002; Liu and Krieger, 2002; López-Revuelta et al., 2006). The phospholipid packing, the membrane fluidity, and the surface charge of liposomes can be modulated and adapted by the cholesterol content, affecting the particle size, encapsulation efficiency, and final morphology (Zhao et al., 2015; Ohvo-Rekilà et al., 2002). Studies have shown that cholesterol as a nonionic molecule has revealed interesting effects on the zeta potential, especially increasing the highest zeta potential of cationic liposomes. The proposed mechanism is reliant on the membrane structure transition and the molecular filling state for the cholesterol-induced charge boosting of cationic liposomes. Cholesterol can induce the phase transition from the crystalline state to the liquid-ordered (LO) phase (Lv et al., 2006; Aramaki et al., 2016). Increasing the amount of cholesterol content in the membrane of liposomes can increase the mean size of liposomes. Due to the hydrophobic nature, cholesterol structure can easily interact with the phospholipid hydrophobic acyl chain through hydrogen bonds and hydrophobic interactions. The ring structure of cholesterol is comparatively inflexible, and its presence stabilizes the protracted straight-chain arrangement of saturated fatty acids via van der Waals interactions (Lee et al., 2005). The Role of Cholesterol-Containing Liposomes in Plasma Stability Cholesterol has a very significant effect on the structural stability of liposomes in plasma (Figure 4). It can reduce the interaction of liposomes with several proteins, leading to less susceptibility to phospholipase, reduce the phospholipid’s loss of high-density lipoproteins, change the membrane enzyme activities, inhibit digestion by macrophages, and inhibit fusion with specific cell types. By changing some liposome features through composition, mostly cholesterol modification, blood clearance and tissue distribution of intravenously injected liposomes can be expected. The cholesterol modification of liposomes has an inhibitory effect on the reticuloendothelial uptake. This modification reduces their interaction with several proteins and probably with serum components, which may affect liposomes’ tissue uptake (D’Avanzo et al., 2011; Johnstone et al., 2001; Moghimi and Patel, 2002). The cholesterol-based liposomal products are presented in Table 7. [Figure: The liposome preparation and the role of cholesterol in its stability.] [Table: Cholesterol-based liposomal products.] The Optimum Cholesterol Concentration for Liposome’s Stability The importance of cholesterol in liposome stability has been described earlier and schematically shows in Figure 3. However, the optimum concentration of cholesterol to attain a suitable formulation has not yet been elucidated. To make stable and regulated drug discharge means, lipids and cholesterol ratio screening arrangements in different studies can help. For the preparation of liposomes, some phospholipids are blended with varying molar ratios of cholesterol. The results of numerous studies have shown that the maximum amount of cholesterol that can be integrated into reconstructed bilayers is assumed to be ∼50 mol%. The most frequently used proportion is the 2: 1 ratio (e.g., two parts of lipids and one part of cholesterol) or 1: 1 ratio; although the underlying reasons for using these ratios is still unknown (Marsh, 2001; Liang et al., 2007; Briuglia et al., 2015). The essential mechanisms of the liposomal interaction with cells according to both, in vitro and in vivo studies have been summarized as: - 1- Particular interfaces with cell-surface components such as electrostatic bonds and imprecise interactions, including feeble hydrophobic bonds - 2- Endocytosis caused by cells of the reticuloendothelial system (RES), comprising neutrophils and macrophages - 3- Combination with the plasma cell membrane by inclusion of the lipid bilayer of the liposome into the plasma membrane (Akbarzadeh et al., 2013) Adjusting cholesterol levels can be a very influential factor in controlling the liposomal stability. This factor can be crucial in designing liposomes for practical use in biological systems in vivo and in vitro (Epstein et al., 2008). The most important commercial liposomes are depicted in Table 8. [Table: Commercial cholesterol-based liposomes.] CLINICAL TRIALS Unlike most nanoparticles, which encounter serious challenges in entering the clinic for various reasons, including safety issues, liposomes are well accepted in the clinic, first liposome-based drug being approved was Doxil®[(Anselmo and Mitragotri, 2015; Bulbake et al., 2017; Singh et al., 2020)], a liposome-based Doxorubicin formulation that has been FDA approved in 1995 for the United States market to treat ovarian cancer and AIDS-related Kaposi’s sarcoma. Subsequently, various other liposomal-based drugs have been commercialized, such as DaunoXome®, for the delivery of daunorubicin, approved in 1996 to manage advanced HIV-associated Kaposi’s sarcoma and several different formulations (Khadke et al., 2020). Currently, many efforts are underway to develop lipid formulations for entry in to the clinics in various fields. To examine the clinical phase studies of liposome-based structures, the term “liposome” was searched from the PubMed database pertaining to various studies related to the clinical phases in the last year. In one study, the effect of liposomal amphotericin B formulation as an antifungal agent was investigated in patients with hematological malignancies with neutropenia and persistent fever (Yoshida et al., 2020). Because fungal infections subsequent to the chemotherapy in patients with neutropenia are considered a severe complication, and as the use of common antifungal drugs is highly toxic, so eliminating this life-threatening complication is very important. The usage of 3 mg/kg/day liposomal amphotericin B concentration for patients was compared with itraconazole; results showed no difference between the liposomal amphotericin B and itraconazole regarding the efficacy and safety in antifungal therapy in hematological malignancy patients (Yoshida et al., 2020). Liposomal compounds are known to be very effective in treating cancer. Recently, another liposomal system has been proposed for the treatment of acute myeloid leukemia wherein the Vyxeos liposome in phase III clinical was examined. This liposomal system comprise two different topoisomerase II inhibitors known as daunorubicin and cytarabine, which included 1 and 0.44 mg in every 1 unit of liposome formulation. The study was performed on elderly patients with untreated acute myeloid leukemia where a higher survival rate for patients treated with the liposomal formulation was discerned than for standard chemotherapy, although some side effects have been reported for the use of this formulation (Tzogani et al., 2020). CONCLUSION Health and medical issues and problems have always been one of the main areas of interest for scientists. Applying new methods for solving medical problems requires introducing new and efficient materials and tools that address related questions and issues. Liposomes have been extensively studied since their introduction, and their potential biomedical use has been well demonstrated. The unique properties of liposomes, including biocompatibility, biodegradability, amphiphilic nature, low toxicity, non-ionicity, sustained release, and active targeting, have made them one of the most widely used nanoparticles. Currently, the most commercialized nanoparticles in the field of drug delivery and cosmetics are related to liposomes. However, they still have some shortcomings that need to be addressed for clinical and pharmaceutical use. As mentioned earlier, since Doxil® introduced in 1995, many efforts have been made to bring these versatile nanomaterials to the clinic; however, their structure still needs to be optimized to reduce some complications. One approach to increase liposomes’ efficiency, especially concerning cancers therapy, is the use of RGD which can be anchored to liposome surfaces or via self-assembly means (Cheng and Ji, 2019). This strategy has been proposed to reduce the side effects of liposomal drugs, as the clinical trial sometimes suffers from, including acute infusion reaction and hand-foot syndrome (HFS). Hence future studies must include new procedures to reduce safety problems (He and Tang, 2018; Cheng and Ji, 2019). Since varying combinations of liposomes can provide unique and distinctive properties, exciting suggestions have been propositioned in the field of novel drug delivery systems, such as nose-to-brain direct drug transport using liposome formulation based on DTE and DTP ingredients (Hong et al., 2019). However, one of the most critical challenges that liposomes encounter is their physical and chemical instability. Various factors such as environmental conditions, manufacturing method, components characteristics, lipid type, and the absence or presence of cholesterol affect liposomes’ stability. The vital need for the development of liposomes with high stability significantly impacts their clinical application. Cholesterol has been shown to increase liposome stability through various mechanisms, including increased retention time, modulating phospholipid packing, Tm, and plasma stability. However, the optimal amount of cholesterol has not yet been identified. Future field research should be based on the principle of finding the optimal amount of cholesterol in liposome production. Notably, cholesterol still tend to maintain membrane’s fluidity as its concentration is increased and decreased. Therefore, the amount of cholesterol and the type of liposome constituents need further investigation. In this context, simulation and computational studies may prove to be very helpful. Hashemzadeh et al. (2020a) have investigated DSPC and DPSM effect on liposome stability through a simulation study which revealed that DSPC preserves its structure shape due to the cylindrical geometric structure and small-size head group, while the DPSM was causing liposome turnover into micelle structure because of its conical geometric design with the larger head group. Such studies regarding cholesterol’s effect on liposome stability via simulation investigations would be highly desirable. AUTHOR CONTRIBUTIONS All authors contributed to the conception and the main idea of the work. MJ, NB, FB, HK, AH, and FM drafted the main text, figures, and tables. MJ supervised the work and provided the comments and additional scientific information. MS and AC-A also reviewed and revised the text. All authors read and approved the final version of the work to be published. CONFLICT OF INTEREST The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. PUBLISHER’S NOTE All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. REFERENCES Abd El-Fattah A. I., Fathy M. M., Ali Z. Y., El-Garawany A. E.-R. A., Mohamed E. K. (2017). Enhanced Therapeutic Benefit of Quercetin-Loaded Phytosome Nanoparticles in Ovariectomized Rats. Chemico-Biological Interactions 271, 30–38. 10.1016/j.cbi.2017.04.026 Abdelkader H., Alani A. W. G., Alany R. G. (2014). Recent Advances in Non-ionic Surfactant Vesicles (Niosomes): Self-Assembly, Fabrication, Characterization, Drug Delivery Applications and Limitations. Drug Deliv. 21 (2), 87–100. 10.3109/10717544.2013.838077 Abu-Dahab R., Schäfer U. F., Lehr C.-M. (2001). Lectin-functionalized Liposomes for Pulmonary Drug Delivery: Effect of Nebulization on Stability and Bioadhesion. Eur. J. Pharm. Sci. 14 (1), 37–46. 10.1016/s0928-0987(01)00147-6 Agarwal R., Katare O. P., Vyas S. P. (2001). Preparation and In Vitro Evaluation of Liposomal/niosomal Delivery Systems for Antipsoriatic Drug Dithranol. Int. J. Pharm. 228 (1-2), 43–52. 10.1016/s0378-5173(01)00810-9 Agrawal M. M., Jawade S., Khan S. (2012). A Review on Liposome. Int. J. Adv. Res. Pharm. Bio Sci. 2 (1), 453–465. Aguilar-Pérez K., Avilés-Castrillo J., Medina D. I., Parra-Saldivar R., Iqbal H. (2020). Insight into Nanoliposomes as Smart Nanocarriers for Greening the Twenty-First century Biomedical Settings. Front. Bioeng. Biotechnol. 8, 1441. 10.3389/fbioe.2020.579536 Ainbinder D., Paolino D., Fresta M., Touitou E. (2010). Drug Delivery Applications with Ethosomes. J Biomed. Nanotechnol 6 (5), 558–568. 10.1166/jbn.2010.1152 Akabori K., Nagle J. F. (2015). Structure of the DMPC Lipid Bilayer Ripple Phase. Soft matter 11 (5), 918–926. 10.1039/c4sm02335h Akbarzadeh A., Rezaei-Sadabady R., Davaran S., Joo S. W., Zarghami N., Hanifehpour Y., et al. (2013). Liposome: Classification, Preparation, and Applications. Nanoscale Res. Lett. 8 (1), 102. 10.1186/1556-276X-8-102 Al-Remawi M., Elsayed A., Maghrabi I., Hamaidi M., Jaber N. (2017). Chitosan/lecithin Liposomal Nanovesicles as an Oral Insulin Delivery System. Pharm. Dev. Technol. 22 (3), 390–398. 10.1080/10837450.2016.1213745 Alizadeh E., Akbarzadeh A., Eslaminejad M. B., Barzegar A., Hashemzadeh S., Nejati-Koshki K., et al. (2015). Up Regulation of Liver-Enriched Transcription Factors HNF4a and HNF6 and Liver-specific MicroRNA (miR-122) by Inhibition of Let-7b in Mesenchymal Stem Cells. Chem. Biol. Drug Des. 85 (3), 268–279. 10.1111/cbdd.12398 AllenLiposomes T. M. (1997). Liposomen. DrugsSuppl 54, 8–14. 10.2165/00003495-199700544-00004 Alving C. R., Rao M., Steers N. J., Matyas G. R., Mayorov A. V. (2012). Liposomes Containing Lipid A: an Effective, Safe, Generic Adjuvant System for Synthetic Vaccines. Expert Rev. Vaccin. 11 (6), 733–744. 10.1586/erv.12.35 Anderson M., Omri A. (2004). The Effect of Different Lipid Components on the In Vitro Stability and Release Kinetics of Liposome Formulations. Drug Deliv. 11 (1), 33–39. 10.1080/10717540490265243 Anselmo A. C., Mitragotri S. (2015). A Review of Clinical Translation of Inorganic Nanoparticles. Aaps J. 17 (5), 1041–1054. 10.1208/s12248-015-9780-2 Anwekar H., Patel S., Singhai A. (2011). Liposome-as Drug Carriers. Int. J. Pharm. Life Sci., 2.(7) Aoki H., Mizuno M., Natsume A., Tsugawa T., Tsujimura K., Takahashi T., et al. (2001). Dendritic Cells Pulsed with Tumor Extract-Cationic Liposome Complex Increase the Induction of Cytotoxic T Lymphocytes in Mouse Brain Tumor. Cancer Immunol. Immunother. 50 (9), 463–468. 10.1007/s002620100220 Aramaki K., Watanabe Y., Takahashi J., Tsuji Y., Ogata A., Konno Y. (2016). Charge Boosting Effect of Cholesterol on Cationic Liposomes. Colloids Surf. A: Physicochemical Eng. Aspects 506, 732–738. 10.1016/j.colsurfa.2016.07.040 Arora R. (2016). Advances in Niosome as a Drug Carrier: a Review. Asian J. Pharmaceutics (Ajp) Free full text articles Asian J Pharm, 1.(1) Ashok B., Arleth L., Hjelm R. P., Rubinstein I., Önyüksel H. (2004). In Vitro characterization of PEGylated Phospholipid Micelles for Improved Drug Solubilization: Effects of PEG Chain Length and PC Incorporation. J. Pharm. Sci. 93 (10), 2476–2487. 10.1002/jps.20150 Asprea M., Tatini F., Piazzini V., Rossi F., Bergonzi M., Bilia A. (2019). Stable, Monodisperse, and Highly Cell-Permeating Nanocochleates from Natural Soy Lecithin Liposomes. Pharmaceutics 11 (1), 34. 10.3390/pharmaceutics11010034 Atrooz O. M. (2011). Efects of Alkylresorcinolic Lipids Obtained from Acetonic Extract of Jordanian Wheat Grains on Liposome Properties. Int. J. Biol. Chem. 5 (5), 314–321. 10.3923/ijbc.2011.314.321 Attia M. F., Anton N., Wallyn J., Omran Z., Vandamme T. F. (2019). An Overview of Active and Passive Targeting Strategies to Improve the Nanocarriers Efficiency to Tumour Sites. J. Pharm. Pharmacol. 71 (8), 1185–1198. 10.1111/jphp.13098 Attwood S., Choi Y., Leonenko Z. (2013). Preparation of DOPC and DPPC Supported Planar Lipid Bilayers for Atomic Force Microscopy and Atomic Force Spectroscopy. Ijms 14 (2), 3514–3539. 10.3390/ijms14023514 Awasthi V. D., Garcia D., Goins B. A., Phillips W. T. (2003). Circulation and Biodistribution Profiles of Long-Circulating PEG-Liposomes of Various Sizes in Rabbits. Int. J. Pharm. 253 (1-2), 121–132. 10.1016/s0378-5173(02)00703-2 Bae Y., Jung M. K., Mun J. Y., Mallick S., Song S. J., Kim D. M., et al. (2018). DQAsomes Nanoparticles Promote Osteogenic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells. Bull. Korean Chem. Soc. 39 (1), 97–104. 10.1002/bkcs.11355 Bakker-Woudenberg I. A. J. M. (2002). Long-circulating Sterically Stabilized Liposomes as Carriers of Agents for Treatment of Infection or for Imaging Infectious Foci. Int. J. Antimicrob. Agents 19 (4), 299–311. 10.1016/s0924-8579(02)00021-3 Barenholz Y. (2016). Chapter 13. Doxil - the First FDA-Approved Nano-Drug: from Basics via CMC, Cell Culture and Animal Studies to Clinical Use. Nanomedicines: Des. Deliv. Detect. 51, 315–345. 10.1039/9781782622536-00315 Barenholz Y. (2021). Doxil - the First FDA-Approved Nano-Drug: From an Idea to a Product. Handbook harnessing Biomater. nanomedicine, 463–528. Jenny Stanford Publishing. 10.1201/9781003125259-16 Barnes L. D., Giuliano E. A., Ota J. (2010). Cellular Localization of Visudyne as a Function of Time after Local Injection in an In Vivo Model of Squamous Cell Carcinoma: an Investigation into Tumor Cell Death. Vet. Ophthalmol. 13 (3), 158–165. 10.1111/j.1463-5224.2010.00775.x Barratt G. (2003). Colloidal Drug Carriers: Achievements and Perspectives. Cell Mol. Life Sci. CMLS 60 (1), 21–37. 10.1007/s000180300002 Battaglia L., Ugazio E. (2019). Lipid nano- and microparticles overview of patent-related research. J. Nanomater. 2019, 2834941. 10.1155/2019/2834941 Baykal-Caglar E., Hassan-Zadeh E., Saremi B., Huang J. (2012). Preparation of Giant Unilamellar Vesicles from Damp Lipid Film for Better Lipid Compositional Uniformity. Biochim. Biophys. Acta (Bba) - Biomembranes 1818 (11), 2598–2604. 10.1016/j.bbamem.2012.05.023 Benech R.-O., Kheadr E. E., Laridi R., Lacroix C., Fliss I. (2002). Inhibition of Listeria Innocua in Cheddar Cheese by Addition of Nisin Z in Liposomes or by In Situ Production in Mixed Culture. Appl. Environ. Microbiol. 68 (8), 3683–3690. 10.1128/aem.68.8.3683-3690.2002 Benesch M., Urban C. (2008). Liposomal Cytarabine for Leukemic and Lymphomatous Meningitis: Recent Developments. Expert Opin. Pharmacother. 9 (2), 301–309. 10.1517/14656566.9.2.301 Bennett W. F. D., MacCallum J. L., Hinner M. J., Marrink S. J., Tieleman D. P. (2009). Molecular View of Cholesterol Flip-Flop and Chemical Potential in Different Membrane Environments. J. Am. Chem. Soc. 131 (35), 12714–12720. 10.1021/ja903529f Benvegnu T., Lemiègre L., Cammas-Marion S. (2009). New Generation of Liposomes Called Archaeosomes Based on Natural or Synthetic Archaeal Lipids as Innovative Formulations for Drug Delivery. Ddf 3 (3), 206–220. 10.2174/187221109789105630 Benz M., Gutsmann T., Chen N., Tadmor R., Israelachvili J. (2004). Correlation of AFM and SFA Measurements Concerning the Stability of Supported Lipid Bilayers. Biophysical J. 86 (2), 870–879. 10.1016/s0006-3495(04)74162-4 Bern C., Adler-Moore J., Berenguer J., Boelaert M., den Boer M., Davidson R. N., et al. (2006). Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis. Clin. Infect. Dis. 43 (7), 917–924. 10.1086/507530 Bhatt P., Lalani R., Vhora I., Patil S., Amrutiya J., Misra A., et al. (2018). Liposomes Encapsulating Native and Cyclodextrin Enclosed Paclitaxel: Enhanced Loading Efficiency and its Pharmacokinetic Evaluation. Int. J. pharmaceutics 536 (1), 95–107. 10.1016/j.ijpharm.2017.11.048 Briuglia M.-L., Rotella C., McFarlane A., Lamprou D. A. (2015). Influence of Cholesterol on Liposome Stability and on In Vitro Drug Release. Drug Deliv. Transl. Res. 5 (3), 231–242. 10.1007/s13346-015-0220-8 B.T.S. Thirumamagal B., Zhao X. B., Bandyopadhyaya A. K., Sureshbabu Narayanasamy S., Johnsamuel J., Tiwari R., et al. (2006). Receptor-targeted Liposomal Delivery of boron-containing Cholesterol Mimics for boron Neutron Capture Therapy (BNCT). Bioconjug. Chem. 17 (5), 1141–1150. 10.1021/bc060075d Bulbake U., Doppalapudi S., Kommineni N., Khan W. (2017). Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 9 (2), 12. 10.3390/pharmaceutics9020012 Burton A. J., Giguère S., Berghaus L. J., Hondalus M. K., Arnold R. D. (2015). Efficacy of Liposomal Gentamicin against Rhodococcus Equi in a Mouse Infection Model and Colocalization with R. Equi in Equine Alveolar Macrophages. Vet. Microbiol. 176 (3-4), 292–300. 10.1016/j.vetmic.2015.01.015 Campbell R. B., Balasubramanian S. V., Straubinger R. M. (2001). Influence of Cationic Lipids on the Stability and Membrane Properties of Paclitaxel‐containing Liposomes. J. Pharm. Sci. 90 (8), 1091–1105. 10.1002/jps.1063 Caracciolo G., Pozzi D., Amenitsch H., Caminiti R. (2005). Multicomponent Cationic Lipid−DNA Complex Formation: Role of Lipid Mixing. Langmuir 21 (25), 11582–11587. 10.1021/la052077c Cardenia V., Waraho T., Rodriguez‐Estrada M. T., Julian McClements D., Decker E. A. (2011). Antioxidant and Prooxidant Activity Behavior of Phospholipids in Stripped Soybean Oil‐in‐Water Emulsions. J. Am. Oil Chem. Soc. 88 (9), 1409–1416. 10.1007/s11746-011-1807-y Carlson D. L., Than K. D., Roberts A. L. (2006). Acid- and Base-Catalyzed Hydrolysis of Chloroacetamide Herbicides. J. Agric. Food Chem. 54 (13), 4740–4750. 10.1021/jf0530704 Chen C., Johnston T. D., Jeon H., Gedaly R., McHugh P. P., Burke T. G., et al. (2009). An In Vitro Study of Liposomal Curcumin: Stability, Toxicity and Biological Activity in Human Lymphocytes and Epstein-Barr Virus-Transformed Human B-Cells. Int. J. Pharm. 366 (1-2), 133–139. 10.1016/j.ijpharm.2008.09.009 Chen C., Han D., Cai C., Tang X. (2010). An Overview of Liposome Lyophilization and its Future Potential. J. controlled release 142 (3), 299–311. 10.1016/j.jconrel.2009.10.024 Chen J.-H., Ling R., Yao Q., Li Y., Chen T., Wang Z., et al. (2005). Effect of Small-Sized Liposomal Adriamycin Administered by Various Routes on a Metastatic Breast Cancer Model. Endocr. Relat. Cancer 12 (1), 93–100. 10.1677/erc.1.00871 Chen J., Lu W.-L., Gu W., Lu S.-S., Chen Z.-P., Cai B.-C., et al. (2014). Drug-in-cyclodextrin-in-liposomes: A Promising Delivery System for Hydrophobic Drugs. Expert Opin. Drug Deliv. 11 (4), 565–577. 10.1517/17425247.2014.884557 Chen X., Wang X., Wang Y., Yang L., Hu J., Xiao W., et al. (2010). Improved Tumor-Targeting Drug Delivery and Therapeutic Efficacy by Cationic Liposome Modified with Truncated bFGF Peptide. J. controlled release 145 (1), 17–25. 10.1016/j.jconrel.2010.03.007 Chen Y., Sun J., Lu Y., Tao C., Huang J., Zhang H., et al. (2013). Complexes Containing Cationic and Anionic pH-Sensitive Liposomes: Comparative Study of Factors Influencing Plasmid DNA Gene Delivery to Tumors. Int. J. Nanomedicine 8, 1573–1593. 10.2147/IJN.S42800 Chen Y., Wu Q., Zhang Z., Yuan L., Liu X., Zhou L. (2012). Preparation of Curcumin-Loaded Liposomes and Evaluation of Their Skin Permeation and Pharmacodynamics. Molecules 17 (5), 5972–5987. 10.3390/molecules17055972 Cheng M. H. Y., Harmatys K. M., Charron D. M., Chen J., Zheng G. (2019). Stable J‐Aggregation of an aza‐BODIPY‐Lipid in a Liposome for Optical Cancer Imaging. Angew. Chem. 131 (38), 13528–13533. 10.1002/ange.201907754 Cheng Y., Ji Y. (2019). RGD-modified Polymer and Liposome Nanovehicles: Recent Research Progress for Drug Delivery in Cancer Therapeutics. Eur. J. Pharm. Sci. 128, 8–17. 10.1016/j.ejps.2018.11.023 Chetoni P., Rossi S., Burgalassi S., Monti D., Mariotti S., Saettone M. F. (2004). Comparison of Liposome-Encapsulated Acyclovir with Acyclovir Ointment: Ocular Pharmacokinetics in Rabbits. J. Ocul. Pharmacol. Ther. 20 (2), 169–177. 10.1089/108076804773710849 Chibowski E., Szcześ A. (2016). Zeta Potential and Surface Charge of DPPC and DOPC Liposomes in the Presence of PLC Enzyme. Adsorption 22 (4-6), 755–765. 10.1007/s10450-016-9767-z Choi M. J., Maibach H. I. (2005). Liposomes and Niosomes as Topical Drug Delivery Systems. Skin Pharmacol. Physiol. 18 (5), 209–219. 10.1159/000086666 Christensen D., Foged C., Rosenkrands I., Lundberg C. V., Andersen P., Agger E. M., et al. (2010). CAF01 Liposomes as a Mucosal Vaccine Adjuvant: In Vitro and In Vivo Investigations. Int. J. pharmaceutics 390 (1), 19–24. 10.1016/j.ijpharm.2009.10.043 Chupin V., Boots J. W. P., Killian J. A., Demel R. A., de Kruijff B. (2002). Thermotropic Phase Behavior of Monoglyceride-Dicetylphosphate Dispersions and Interactions with Proteins: a 2H and 31P NMR Study. Biophysical J. 82 (2), 843–851. 10.1016/s0006-3495(02)75446-5 Collier M. A., Bachelder E. M., Ainslie K. M. (2017). Electrosprayed Myocet-like Liposomes: an Alternative to Traditional Liposome Production. Pharm. Res. 34 (2), 419–426. 10.1007/s11095-016-2072-4 Cordeiro C., Wiseman D. J., Lutwyche P., Uh M., Evans J. C., Finlay B. B., et al. (2000). Antibacterial Efficacy of Gentamicin Encapsulated in pH-Sensitive Liposomes against an In Vivo Salmonella enterica Serovar Typhimurium Intracellular Infection Model. Antimicrob. Agents Chemother. 44 (3), 533–539. 10.1128/aac.44.3.533-539.2000 Crommelin D. J. A., van Hoogevest P., Storm G. (2020). The Role of Liposomes in Clinical Nanomedicine Development. What Now? Now what?. J. Controlled Release 318, 256–263. 10.1016/j.jconrel.2019.12.023 Csiszár A., Hersch N., Dieluweit S., Biehl R., Merkel R., Hoffmann B. (2010). Novel Fusogenic Liposomes for Fluorescent Cell Labeling and Membrane Modification. Bioconjug. Chem. 21 (3), 537–543. 10.1021/bc900470y D'Avanzo N., Hyrc K., Enkvetchakul D., Covey D. F., Nichols C. G. (2011). Enantioselective Protein-Sterol Interactions Mediate Regulation of Both Prokaryotic and Eukaryotic Inward Rectifier K+ Channels by Cholesterol. PLoS One 6 (4), e19393. 10.1371/journal.pone.0019393 Daemen T., Demare A., Bungener L., Dejonge J., Huckriede A., Wilschut J. (2005). Virosomes for Antigen and DNA Delivery. Adv. Drug Deliv. Rev. 57 (3), 451–463. 10.1016/j.addr.2004.09.005 Dana P., Bunthot S., Suktham K., Surassmo S., Yata T., Namdee K., et al. (2020). Active Targeting Liposome-PLGA Composite for Cisplatin Delivery against Cervical Cancer. Colloids Surf. B: Biointerfaces 196, 111270. 10.1016/j.colsurfb.2020.111270 Daraee H., Etemadi A., Kouhi M., Alimirzalu S., Akbarzadeh A. (2016). Application of Liposomes in Medicine and Drug Delivery. Artif. Cell Nanomedicine, Biotechnol. 44 (1), 381–391. 10.3109/21691401.2014.953633 Davidsen J., Rosenkrands I., Christensen D., Vangala A., Kirby D., Perrie Y., et al. (2005). Characterization of Cationic Liposomes Based on Dimethyldioctadecylammonium and Synthetic Cord Factor from M. tuberculosis (Trehalose 6,6'-Dibehenate)-A Novel Adjuvant Inducing Both strong CMI and Antibody Responses. Biochim. Biophys. Acta 1718 (1-2), 22–31. 10.1016/j.bbamem.2005.10.011 Davidson E. M., Haroutounian S., Kagan L., Naveh M., Aharon A., Ginosar Y. (2016). A Novel Proliposomal Ropivacaine Oil. Anesth. Analgesia 122 (5), 1663–1672. 10.1213/ane.0000000000001200 Dayan N., Touitou E. (2000). Carriers for Skin Delivery of Trihexyphenidyl HCl: Ethosomes vs. Liposomes. Biomaterials 21 (18), 1879–1885. 10.1016/s0142-9612(00)00063-6 Demetzos C. (2008). Differential Scanning Calorimetry (DSC): a Tool to Study the thermal Behavior of Lipid Bilayers and Liposomal Stability. J. liposome Res. 18 (3), 159–173. 10.1080/08982100802310261 Deng H., Song K., Zhao X., Li Y., Wang F., Zhang J., et al. (2017). Tumor Microenvironment Activated Membrane Fusogenic Liposome with Speedy Antibody and Doxorubicin Delivery for Synergistic Treatment of Metastatic Tumors. ACS Appl. Mater. Inter. 9 (11), 9315–9326. 10.1021/acsami.6b14683 Deng M., Tu N., Bai F., Wang L. (2012). Surface Functionalization of Hydrophobic Nanocrystals with One Particle Per Micelle for Bioapplications. Chem. Mater. 24 (13), 2592–2597. 10.1021/cm301285g Deniz A., Sade A., Severcan F., Keskin D., Tezcaner A., Banerjee S. (2010). Celecoxib-loaded Liposomes: Effect of Cholesterol on Encapsulation and In Vitro Release Characteristics. Biosci. Rep. 30 (5), 365–373. 10.1042/bsr20090104 Devrim B., Kara A., Vural İ., Bozkır A. (2016). Lysozyme-loaded Lipid-Polymer Hybrid Nanoparticles: Preparation, Characterization and Colloidal Stability Evaluation. Drug Dev. Ind. Pharm. 42 (11), 1865–1876. 10.1080/03639045.2016.1180392 Dokka S., Toledo D., Shi X., Castranova V., Rojanasakul Y. (2000). Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes. Pharm. Res. 17 (5), 521–525. 10.1023/a:1007504613351 Domínguez A. R., Hidalgo D. O., Garrido R. V., Sánchez E. T. (2005). Liposomal Cytarabine (DepoCyte) for the Treatment of Neoplastic Meningitis. Clin. Transl Oncol. 7 (6), 232–238. 10.1007/bf02710168 Dos Santos N., Mayer L. D., Abraham S. A., Gallagher R. C., Cox K. A. K., Tardi P. G., et al. (2002). Improved Retention of Idarubicin after Intravenous Injection Obtained for Cholesterol-free Liposomes. Biochim. Biophys. Acta (Bba) - Biomembranes 1561 (2), 188–201. 10.1016/s0005-2736(02)00345-0 Drin G., Morello V., Casella J.-F., Gounon P., Antonny B. (2008). Asymmetric Tethering of Flat and Curved Lipid Membranes by a Golgin. Science 320 (5876), 670–673. 10.1126/science.1155821 Drulis-Kawa Z., Dorotkiewicz-Jach A. (2010). Liposomes as Delivery Systems for Antibiotics. Int. J. Pharm. 387 (1-2), 187–198. 10.1016/j.ijpharm.2009.11.033 Dua J., Rana A., Bhandari A. (2012). Liposome: Methods of Preparation and Applications. Int. J. Pharm. Stud. Res. 3 (2), 14–20. Ducat E., Deprez J., Gillet A., Noël A., Evrard B., Peulen O., et al. (2011). Nuclear Delivery of a Therapeutic Peptide by Long Circulating pH-Sensitive Liposomes: Benefits over Classical Vesicles. Int. J. pharmaceutics 420 (2), 319–332. 10.1016/j.ijpharm.2011.08.034 Düzgünes N., Simões S., Slepushkin V., Pretzer E., Rossi J. J., De Clercq E., et al. (2001). Enhanced Inhibition of HIV-1 Replication in Macrophages by Antisense Oligonucleotides, Ribozymes and Acyclic Nucleoside Phosphonate Analogs Delivered in pH-Sensitive Liposomes. Nucleosides Nucleotides Nucleic Acids 20 (4-7), 515–523. 10.1081/NCN-100002327 Dynarowicz-Łątka P., Seoane R., Minones J., Jr, Velo M., Minones J. (2003). Study of Penetration of Amphotericin B into Cholesterol or Ergosterol Containing Dipalmitoyl Phosphatidylcholine Langmuir Monolayers. Colloids Surf. B: Biointerfaces 27 (2-3), 249–263. El-Samaligy M. S., Afifi N. N., Mahmoud E. A. (2006). Evaluation of Hybrid Liposomes-Encapsulated Silymarin Regarding Physical Stability and In Vivo Performance. Int. J. Pharm. 319 (1-2), 121–129. 10.1016/j.ijpharm.2006.04.023 El-Samaligy M. S., Afifi N. N., Mahmoud E. A. (2006). Increasing Bioavailability of Silymarin Using a Buccal Liposomal Delivery System: Preparation and Experimental Design Investigation. Int. J. Pharm. 308 (1-2), 140–148. 10.1016/j.ijpharm.2005.11.006 Ellis M., Bernsen R., Ali-Zadeh H., Kristensen J., Hedström U., Poughias L., et al. (2009). A Safety and Feasibility Study Comparing an Intermittent High Dose with a Daily Standard Dose of Liposomal Amphotericin B for Persistent Neutropenic Fever. J. Med. Microbiol. 58 (11), 1474–1485. 10.1099/jmm.0.012401-0 Eloy J. O., Claro de Souza M., Petrilli R., Barcellos J. P. A., Lee R. J., Marchetti J. M. (2014). Liposomes as Carriers of Hydrophilic Small Molecule Drugs: Strategies to Enhance Encapsulation and Delivery. Colloids Surf. B: Biointerfaces 123, 345–363. 10.1016/j.colsurfb.2014.09.029 Epstein H., Gutman D., Cohen-Sela E., Haber E., Elmalak O., Koroukhov N., et al. (2008). Preparation of Alendronate Liposomes for Enhanced Stability and Bioactivity: In Vitro and In Vivo Characterization. Aaps J. 10 (4), 505–515. 10.1208/s12248-008-9060-5 Evjen T. J., Nilssen E. A., Barnert S., Schubert R., Brandl M., Fossheim S. L. (2011). Ultrasound-mediated Destabilization and Drug Release from Liposomes Comprising Dioleoylphosphatidylethanolamine. Eur. J. Pharm. Sci. 42 (4), 380–386. 10.1016/j.ejps.2011.01.002 Fang J.-Y., Fang C.-L., Liu C.-H., Su Y.-H. (2008). Lipid Nanoparticles as Vehicles for Topical Psoralen Delivery: Solid Lipid Nanoparticles (SLN) versus Nanostructured Lipid Carriers (NLC). Eur. J. Pharmaceutics Biopharmaceutics 70 (2), 633–640. 10.1016/j.ejpb.2008.05.008 Fang J.-Y., Hung C.-F., Hwang T.-L., Huang Y.-L. (2005). Physicochemical Characteristics Andin Vivodeposition of Liposome-Encapsulated tea Catechins by Topical and Intratumor Administrations. J. Drug Target. 13 (1), 19–27. 10.1080/10611860400015977 Farzad N., Barati N., Momtazi-Borojeni A. A., Yazdani M., Arab A., Razazan A., et al. (2019). P435 HER2/neu-Derived Peptide Conjugated to Liposomes Containing DOPE as an Effective Prophylactic Vaccine Formulation for Breast Cancer. Artif. Cell Nanomedicine, Biotechnol. 47 (1), 664–672. 10.1080/21691401.2019.1576702 Fattal E., Couvreur P., Dubernet C. (2004). "Smart" Delivery of Antisense Oligonucleotides by Anionic pH-Sensitive Liposomes. Adv. Drug Deliv. Rev. 56 (7), 931–946. 10.1016/j.addr.2003.10.037 Faustino C. M. C., Calado A. R. T., Garcia-Rio L. (2011). Mixed Micelle Formation between Amino Acid-Based Surfactants and Phospholipids. J. Colloid Interf. Sci. 359 (2), 493–498. 10.1016/j.jcis.2011.04.016 Felnerova D., Viret J.-F., Glück R., Moser C. (2004). Liposomes and Virosomes as Delivery Systems for Antigens, Nucleic Acids and Drugs. Curr. Opin. Biotechnol. 15 (6), 518–529. 10.1016/j.copbio.2004.10.005 Figueroa-Robles A., Antunes-Ricardo M., Guajardo-Flores D. (2020). Encapsulation of Phenolic Compounds with Liposomal Improvement in the Cosmetic Industry. Int. J. Pharm. 593, 120125. 10.1016/j.ijpharm.2020.120125 Franzé S., Selmin F., Samaritani E., Minghetti P., Cilurzo F. (2018). Lyophilization of Liposomal Formulations: Still Necessary, Still Challenging. Pharmaceutics 10 (3), 139. 10.3390/pharmaceutics10030139 Freedman M., Chang E. H., Zhou Q., Pirollo K. F. (2009). Nanodelivery of MRI Contrast Agent Enhances Sensitivity of Detection of Lung Cancer Metastases. Acad. Radiol. 16 (5), 627–637. 10.1016/j.acra.2008.12.002 Frenzel M., Steffen-Heins A. (2015). Whey Protein Coating Increases Bilayer Rigidity and Stability of Liposomes in Food-like Matrices. Food Chem. 173, 1090–1099. 10.1016/j.foodchem.2014.10.076 Fuchsluger T. A., Hintschich C., Steuhl K.-P., Meller D. (2006). Adjuvante topische Interferon-α-2b-Therapie bei epithelialen Tumoren der Augenoberfläche. Ophthalmologe 103 (2), 124–128. 10.1007/s00347-005-1249-8 Fujisawa T., Miyai H., Hironaka K., Tsukamoto T., Tahara K., Tozuka Y., et al. (2012). Liposomal Diclofenac Eye Drop Formulations Targeting the Retina: Formulation Stability Improvement Using Surface Modification of Liposomes. Int. J. Pharm. 436 (1-2), 564–567. 10.1016/j.ijpharm.2012.07.024 Gabriëls M., Plaizier-Vercammen J. (2003). Physical and Chemical Evaluation of Liposomes, Containing Artesunate. J. Pharm. Biomed. Anal. 31 (4), 655–667. 10.1016/s0731-7085(02)00678-7 Garbuzenko O., Barenholz Y., Priev A. (2005). Effect of Grafted PEG on Liposome Size and on Compressibility and Packing of Lipid Bilayer. Chem. Phys. Lipids 135 (2), 117–129. 10.1016/j.chemphyslip.2005.02.003 Garg T., K. Goyal A. (2014). Liposomes: Targeted and Controlled Delivery System. Ddl 4 (1), 62–71. 10.2174/22103031113036660015 Ghanbarzadeh S., Valizadeh H., Zakeri-Milani P. (2013). The Effects of Lyophilization on the Physico-Chemical Stability of Sirolimus Liposomes. Adv. Pharm. Bull. 3 (1), 25–29. 10.5681/apb.2013.005 Ghazizadeh E., Neshastehriz A. (2020). Different Liposome Patterns to Detection of Acute Leukemia Based on Electrochemical Cell Sensor. Analytica Chim. Acta. Giulimondi F., Digiacomo L., Pozzi D., Palchetti S., Vulpis E., Capriotti A. L., et al. (2019). Interplay of Protein corona and Immune Cells Controls Blood Residency of Liposomes. Nat. Commun. 10 (1), 3686–3711. 10.1038/s41467-019-11642-7 Goto T., Morishita M., Nishimura K., Nakanishi M., Kato A., Ehara J., et al. (2006). Novel Mucosal Insulin Delivery Systems Based on Fusogenic Liposomes. Pharm. Res. 23 (2), 384–391. 10.1007/s11095-005-9175-7 Gross N., Ranjbar M., Evers C., Hua J., Martin G., Schulze B., et al. (2013). Choroidal Neovascularization Reduced by Targeted Drug Delivery with Cationic Liposome-Encapsulated Paclitaxel or Targeted Photodynamic Therapy with Verteporfin Encapsulated in Cationic Liposomes. Mol. Vis. 19, 54–61. Gullapalli R. R., Demirel M. C., Butler P. J. (2008). Molecular Dynamics Simulations of DiI-C18(3) in a DPPC Lipid Bilayer. Phys. Chem. Chem. Phys. 10 (24), 3548–3560. 10.1039/b716979e Hadavi R., Jafari S. M., Katouzian I. (2020). Nanoliposomal Encapsulation of Saffron Bioactive Compounds; Characterization and Optimization. Int. J. Biol. Macromolecules 164, 4046–4053. 10.1016/j.ijbiomac.2020.09.028 Hahn V., Friedt W. (2012). Important Characters by Recombinant DNA Technology. Prog. Bot. Stuctural Bot. Physiol. Genet. Taxonomy Geobotany/Fortschritte der Botanik Struktur Physiologie Genetik Systematik Geobotanik 53, 181. Hashemzadeh H., Javadi H., Darvishi M. H. (2020). Study of Structural Stability and Formation Mechanisms in DSPC and DPSM Liposomes: A Coarse-Grained Molecular Dynamics Simulation. Sci. Rep. 10 (1), 1837–1910. 10.1038/s41598-020-58730-z Hashemzadeh H., Javadi H., Darvishi M. H. (2020). Study of Structural Stability and Formation Mechanisms in DSPC and DPSM Liposomes: A Coarse-Grained Molecular Dynamics Simulation. Sci. Rep. 10 (1), 1837. 10.1038/s41598-020-58730-z Hathout R. M., Mansour S., Mortada N. D., Guinedi A. S. (2007). Liposomes as an Ocular Delivery System for Acetazolamide: In Vitro and In Vivo Studies. Aaps Pharmscitech 8 (1), E1–E12. 10.1208/pt0801001 He J., Evers D. L., O’Leary T. J., Mason J. T. (2012). Immunoliposome-PCR: a Generic Ultrasensitive Quantitative Antigen Detection System. J. nanobiotechnology 10 (1), 26. 10.1186/1477-3155-10-26 He K., Tang M. (2018). Safety of Novel Liposomal Drugs for Cancer Treatment: Advances and Prospects. Chemico-Biological Interactions 295, 13–19. 10.1016/j.cbi.2017.09.006 Hilmer S. N., Cogger V. C., Muller M., Le Couteur D. G. (2004). The Hepatic Pharmacokinetics of Doxorubicin and Liposomal Doxorubicin. Drug Metab. Dispos 32 (8), 794–799. 10.1124/dmd.32.8.794 Hirano M., Nakamura S., Mitsunaga F., Okada M., Shimuzu K., Imamura T. (2002). Transfer of Maternally Administered Fusogenic Liposome-DNA Complexes into Monkey Fetuses in a Pregnancy Model. J. Gene Med. 4 (5), 560–566. 10.1002/jgm.289 Ho J. A., Zeng S. C., Huang M. R., Kuo H. Y. (2006). Development of Liposomal Immunosensor for the Measurement of Insulin with Femtomole Detection. Anal. Chim. Acta 556 (1), 127–132. 10.1016/j.aca.2005.08.074 Homann H.-H., Rosbach O., Moll W., Vogt P. M., Germann G., Hopp M., et al. (2007). A Liposome Hydrogel with Polyvinyl-Pyrrolidone Iodine in the Local Treatment of Partial-Thickness Burn Wounds. Ann. Plast. Surg. 59 (4), 423–427. 10.1097/sap.0b013e3180326fcf Hong S.-S., Oh K. T., Choi H.-G., Lim S.-J. (2019). Liposomal Formulations for Nose-To-Brain Delivery: Recent Advances and Future Perspectives. Pharmaceutics 11 (10), 540. 10.3390/pharmaceutics11100540 Hosny K. M. (2010). Ciprofloxacin as Ocular Liposomal Hydrogel. Aaps Pharmscitech 11 (1), 241–246. 10.1208/s12249-009-9373-4 Hu Q., Bally M. B., Madden T. D. (2002). Subcellular Trafficking of Antisense Oligonucleotides and Down-Regulation of Bcl-2 Gene Expression in Human Melanoma Cells Using a Fusogenic Liposome Delivery System. Nucleic Acids Res. 30 (16), 3632–3641. 10.1093/nar/gkf448 Hua S. (2013). Targeting Sites of Inflammation: Intercellular Adhesion Molecule-1 as a Target for Novel Inflammatory Therapies. Front. Pharmacol. 4, 127. 10.3389/fphar.2013.00127 Huang F.-Y. J., Hung C.-C., Chang C.-W., Chao J.-H., Hsieh B.-T. (2018). Evaluation of Injectable Chitosan-Based Co-cross-linking Hydrogel for Local Delivery of 188Re-LIPO-DOX to Breast-Tumor-Bearing Mouse Model. Anticancer Res. 38 (8), 4651–4659. 10.21873/anticanres.12770 Huh S. Y., Shin J. W., Na J. I., Huh C. H., Youn S. W., Park K. C. (2010). Efficacy and Safety of Liposome-Encapsulated 4-N-Butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-Face Trial. J. Dermatol. 37 (4), 311–315. 10.1111/j.1346-8138.2010.00787.x Husain S., Capitano B., Corcoran T., Studer S. M., Crespo M., Johnson B., et al. (2010). Intrapulmonary Disposition of Amphotericin B after Aerosolized Delivery of Amphotericin B Lipid Complex (Abelcet; ABLC) in Lung Transplant Recipients. Transplantation 90 (11), 1215–1219. 10.1097/tp.0b013e3181f995ea Ib G., Corredig M. (2013). Storage Stability and Physical Characteristics of tea-polyphenol-bearing Nanoliposomes Prepared with Milk Fat Globule Membrane Phospholipids. J. Agric. Food Chem. 61 (13), 3242–3251. Ichikawa K., Hikita T., Maeda N., Takeuchi Y., Namba Y., Oku N. (2004). PEGylation of Liposome Decreases the Susceptibility of Liposomal Drug in Cancer Photodynamic Therapy. Biol. Pharm. Bull. 27 (3), 443–444. 10.1248/bpb.27.443 Ichikawa K., Hikita T., Maeda N., Yonezawa S., Takeuchi Y., Asai T., et al. (2005). Antiangiogenic Photodynamic Therapy (PDT) by Using Long-Circulating Liposomes Modified with Peptide Specific to Angiogenic Vessels. Biochim. Biophys. Acta (Bba) - Biomembranes 1669 (1), 69–74. 10.1016/j.bbamem.2005.02.003 Jacoby G., Cohen K., Barkan K., Talmon Y., Peer D., Beck R. (2015). Metastability in Lipid Based Particles Exhibits Temporally Deterministic and Controllable Behavior. Sci. Rep. 5, 9481. 10.1038/srep09481 Jain A., Jain S. K. (2016). In Vitro release Kinetics Model Fitting of Liposomes: An Insight. Chem. Phys. Lipids 201, 28–40. 10.1016/j.chemphyslip.2016.10.005 Jain A. K., Thanki K., Jain S. (2014). Solidified Self-Nanoemulsifying Formulation for Oral Delivery of Combinatorial Therapeutic Regimen: Part I. Formulation Development, Statistical Optimization, and In Vitro Characterization. Pharm. Res. 31 (4), 923–945. 10.1007/s11095-013-1213-2 Jain M., Zellweger M., Frobert A., Valentin J., Bergh H. v. d., Wagnières G., et al. (2016). Intra-Arterial Drug and Light Delivery for Photodynamic Therapy Using Visudyne: Implication for Atherosclerotic Plaque Treatment. Front. Physiol. 7, 400. 10.3389/fphys.2016.00400 Jain N., Gupta B. P., Thakur N., Jain R., Banweer J., Jain D. K., et al. (2010). Phytosome: a Novel Drug Delivery System for Herbal Medicine. Int. J. Pharm. Sci. Drug Res. 2 (4), 224–228. Jeon M., Kim G., Lee W., Im H-J. (2020). Development of Theranostic PEGylated Liposomal Au-Liposome for Effective Tumor Passive Targeting and Photothermal Therapy. Soc. Nucl. Med 61, 1076. Jimbo T., Sakuma Y., Urakami N., Ziherl P., Imai M. (2016). Role of Inverse-Cone-Shape Lipids in Temperature-Controlled Self-Reproduction of Binary Vesicles. Biophysical J. 110 (7), 1551–1562. 10.1016/j.bpj.2016.02.028 Jiménez-Escrig A., Sánchez-Muniz F. J. (2000). Dietary Fibre from Edible Seaweeds: Chemical Structure, Physicochemical Properties and Effects on Cholesterol Metabolism. Nutr. Res. 20 (4), 585–598. 10.1016/s0271-5317(00)00149-4 Johnston M. J. W., Semple S. C., Klimuk S. K., Ansell S., Maurer N., Cullis P. R. (2007). Characterization of the Drug Retention and Pharmacokinetic Properties of Liposomal Nanoparticles Containing Dihydrosphingomyelin. Biochim. Biophys. Acta (Bba) - Biomembranes 1768 (5), 1121–1127. 10.1016/j.bbamem.2007.01.019 Johnstone S. A., Masin D., Mayer L., Bally M. B. (2001). Surface-associated Serum Proteins Inhibit the Uptake of Phosphatidylserine and Poly(ethylene Glycol) Liposomes by Mouse Macrophages. Biochim. Biophys. Acta (Bba) - Biomembranes 1513 (1), 25–37. 10.1016/s0005-2736(01)00292-9 Joly F., Ray-Coquard I., Fabbro M., Donoghoe M., Boman K., Sugimoto A., et al. (2011). Decreased Hypersensitivity Reactions with Carboplatin-Pegylated Liposomal Doxorubicin Compared to Carboplatin-Paclitaxel Combination: Analysis from the GCIG CALYPSO Relapsing Ovarian Cancer Trial. Gynecol. Oncol. 122 (2), 226–232. 10.1016/j.ygyno.2011.04.019 Joshi S., Hussain M. T., Roces C. B., Anderluzzi G., Kastner E., Salmaso S., et al. (2016). Microfluidics Based Manufacture of Liposomes Simultaneously Entrapping Hydrophilic and Lipophilic Drugs. Int. J. pharmaceutics 514 (1), 160–168. 10.1016/j.ijpharm.2016.09.027 Jung H.-S., Ishii H., Shimanouchi T., Umakoshi H., Kuboi R. (2007). Immobilized-liposome Sensor System for Detection of Proteins under Stress Conditions. Membrane 32 (5), 294–301. 10.5360/membrane.32 Jung J. H., Ree M., Kim H. (2006). Acid-and Base-Catalyzed Hydrolyses of Aliphatic Polycarbonates and Polyesters. Catal. Today 115 (1-4), 283–287. 10.1016/j.cattod.2006.02.060 Jung S.-Y., Holden M. A., Cremer P. S., Collier C. P. (2005). Two-Component Membrane Lithography via Lipid Backfilling. ChemPhysChem. 6 (3), 423–426. 10.1002/cphc.200400540 Jung S. H., Jung S. H., Seong H., Cho S. H., Jeong K. S., Shin B. C. (2009). Polyethylene Glycol-Complexed Cationic Liposome for Enhanced Cellular Uptake and Anticancer Activity. Int. J. Pharm. 382 (1-2), 254–261. 10.1016/j.ijpharm.2009.08.002 Park J. W., Benz C. C., Martin F. J. (2004). in Future Directions of Liposome-And Immunoliposome-Based Cancer Therapeutics. Seminars in Oncology (Elsevier; ).Kafle A., Akamatsu M., Bhadani A., Sakai K., Kaise C., Kaneko T., et al. (2020). Phase Behavior of the Bilayers Containing Hydrogenated Soy Lecithin and β-sitosteryl Sulfate. Langmuir. 10.1021/acs.langmuir.0c00472 Kang S. H., Cho H.-J., Shim G., Lee S., Kim S.-H., Choi H.-G., et al. (2011). Cationic Liposomal Co-delivery of Small Interfering RNA and a MEK Inhibitor for Enhanced Anticancer Efficacy. Pharm. Res. 28 (12), 3069–3078. 10.1007/s11095-011-0569-4 Karmali P. P., Chaudhuri A. (2007). Cationic Liposomes as Non-viral Carriers of Gene Medicines: Resolved Issues, Open Questions, and Future Promises. Med. Res. Rev. 27 (5), 696–722. 10.1002/med.20090 Kashapov R., Ibragimova A., Pavlov R., Gabdrakhmanov D., Kashapova N., Burilova E., et al. (2021). Nanocarriers for Biomedicine: From Lipid Formulations to Inorganic and Hybrid Nanoparticles. Ijms 22 (13), 7055. 10.3390/ijms22137055 Kaur G., Garg T., Rath G., Goyal A. K. (2016). Archaeosomes: an Excellent Carrier for Drug and Cell Delivery. Drug Deliv. 23 (7), 2497–2512. 10.3109/10717544.2015.1019653 Khadke S., Roces C. B., Donaghey R., Giacobbo V., Su Y., Perrie Y. (2020). Scalable Solvent-free Production of Liposomes. J. Pharm. Pharmacol. 72 (10), 1328–1340. 10.1111/jphp.13329 Khosravi-Darani K., Zahed O., Aarabi S. (2018). Antioxidant activity of Zataria multiflora boiss. Essential oil encapsulated in nanoliposome in broth media and minced beef. Pak. J. Biotechnol. 15 (2), 365–375. Kidd P. M. (2009). Bioavailability and Activity of Phytosome Complexes from Botanical Polyphenols: the Silymarin, Curcumin, green tea, and Grape Seed Extracts. Altern. Med. Rev. 14 (3), 226–246. Kitayama H., Takechi Y., Tamai N., Matsuki H., Yomota C., Saito H. (2014). Thermotropic Phase Behavior of Hydrogenated Soybean Phosphatidylcholine-Cholesterol Binary Liposome Membrane. Chem. Pharm. Bull. 62 (1), 58–63. 10.1248/cpb.c13-00587 Kleusch C., Hersch N., Hoffmann B., Merkel R., Csiszár A. (2012). Fluorescent Lipids: Functional Parts of Fusogenic Liposomes and Tools for Cell Membrane Labeling and Visualization. Molecules 17 (1), 1055–1073. 10.3390/molecules17011055 Kshirsagar N. A., Pandya S. K., Kirodian G. B., Sanath S. (2005). Liposomal Drug Delivery System from Laboratory to Clinic. J. Postgrad. Med. 51 Suppl 1 (5), S5–S15. Kunisawa J., Masuda T., Katayama K., Yoshikawa T., Tsutsumi Y., Akashi M., et al. (2005). Fusogenic Liposome Delivers Encapsulated Nanoparticles for Cytosolic Controlled Gene Release. J. controlled release 105 (3), 344–353. 10.1016/j.jconrel.2005.03.020 Kunzelmann-Marche C., Freyssinet J.-M., Martínez M. C. (2002). Loss of Plasma Membrane Phospholipid Asymmetry Requires Raft Integrity. J. Biol. Chem. 277 (22), 19876–19881. 10.1074/jbc.m200324200 Laouini A., Jaafar-Maalej C., Limayem-Blouza I., Sfar S., Charcosset C., Fessi H. (2012). Preparation, Characterization and Applications of Liposomes: State of the Art. J Coll. Sci. Biotechnol. 1 (2), 147–168. 10.1166/jcsb.2012.1020 Lebègue E., Anderson C. M., Dick J. E., Webb L. J., Bard A. J. (2015). Electrochemical Detection of Single Phospholipid Vesicle Collisions at a Pt Ultramicroelectrode. Langmuir 31 (42), 11734–11739. 10.1021/acs.langmuir.5b03123 Lee C. M., Flynn R., Hollywood J. A., Scallan M. F., Harrison P. T. (2012). Correction of the ΔF508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene by Zinc-Finger Nuclease Homology-Directed Repair. BioResearch open access 1 (3), 99–108. 10.1089/biores.2012.0218 Lee J., Kim H.-J., Kim J. (2008). Polydiacetylene Liposome Arrays for Selective Potassium Detection. J. Am. Chem. Soc. 130 (15), 5010–5011. 10.1021/ja709996c Lee S. C., Lee K. E., Kim J. J., Lim S. H. (2005). The Effect of Cholesterol in the Liposome Bilayer on the Stabilization of Incorporated Retinol. J. Liposome Res. 15 (3-4), 157–166. 10.1080/08982100500364131 Li J., Wang X., Zhang T., Wang C., Huang Z., Luo X., et al. (2015). A Review on Phospholipids and Their Main Applications in Drug Delivery Systems. Asian J. Pharm. Sci. 10 (2), 81–98. 10.1016/j.ajps.2014.09.004 Li M., Du C., Guo N., Teng Y., Meng X., Sun H., et al. (2019). Composition Design and Medical Application of Liposomes. Eur. J. Med. Chem. 164, 640–653. 10.1016/j.ejmech.2019.01.007 Liang L. P. T. H. J., Chung T. W., Liu Y. Y. H. D. Z. (2007). Liposomes Incorporated with Cholesterol for Drug Release Triggered by Magnetic Field. J. Med. Biol. Eng. 27 (1), 29–34. Liang X. F., Wang H. J., Luo H., Tian H., Zhang B. B., Hao L. J., et al. (2008). Characterization of Novel Multifunctional Cationic Polymeric Liposomes Formed from Octadecyl Quaternized Carboxymethyl Chitosan/cholesterol and Drug Encapsulation. Langmuir 24 (14), 7147–7153. 10.1021/la703775a Lira R. B., Seabra M. A. B. L., Matos A. L. L., Vasconcelos J. V., Bezerra D. P., de Paula E., et al. (2013). Studies on Intracellular Delivery of Carboxyl-Coated CdTe Quantum Dots Mediated by Fusogenic Liposomes. J. Mater. Chem. B 1 (34), 4297–4305. 10.1039/c3tb20245c Liu B., Krieger M. (2002). Highly Purified Scavenger Receptor Class B, Type I Reconstituted into Phosphatidylcholine/cholesterol Liposomes Mediates High Affinity High Density Lipoprotein Binding and Selective Lipid Uptake. J. Biol. Chem. 277 (37), 34125–34135. 10.1074/jbc.m204265200 Liu W. L., Zou M. Z., Qin S. Y., Cheng Y. J., Ma Y. H., Sun Y. X., et al. (2020). Recent Advances of Cell Membrane‐Coated Nanomaterials for Biomedical Applications. Adv. Funct. Mater. 30 (39), 2003559. 10.1002/adfm.202003559 Liu X., Madhankumar A. B., Miller P. A., Duck K. A., Hafenstein S., Rizk E., et al. (2016). MRI Contrast Agent for Targeting Glioma: Interleukin-13 Labeled Liposome Encapsulating Gadolinium-DTPA. Neuro Oncol. 18 (5), 691–699. 10.1093/neuonc/nov263 Liu Y., Castro Bravo K. M., Liu J. (2021). Targeted Liposomal Drug Delivery: a Nanoscience and Biophysical Perspective. Nanoscale Horiz. 6 (2), 78–94. 10.1039/d0nh00605j López-Pinto J. M., González-Rodríguez M. L., Rabasco A. M. (2005). Effect of Cholesterol and Ethanol on Dermal Delivery from DPPC Liposomes. Int. J. pharmaceutics 298 (1), 1–12. 10.1016/j.ijpharm.2005.02.021 López-Revuelta A., Sánchez-Gallego J. I., Hernández-Hernández A., Sánchez-Yagüe J., Llanillo M. (2006). Membrane Cholesterol Contents Influence the Protective Effects of Quercetin and Rutin in Erythrocytes Damaged by Oxidative Stress. Chemico-biological interactions 161 (1), 79–91. 10.1016/j.cbi.2006.03.004 Lowis S., Lewis I., Lewis I., Elsworth A., Weston C., Doz F., et al. (2006). A Phase I Study of Intravenous Liposomal Daunorubicin (DaunoXome) in Paediatric Patients with Relapsed or Resistant Solid Tumours. Br. J. Cancer 95 (5), 571–580. 10.1038/sj.bjc.6603288 Lu F. S. H., Nielsen N. S., Baron C. P., Jensen L. H. S., Jacobsen C. (2012). Physico-chemical Properties of marine Phospholipid Emulsions. J. Am. Oil Chem. Soc. 89 (11), 2011–2024. 10.1007/s11746-012-2105-z Lv H., Zhang S., Wang B., Cui S., Yan J. (2006). Toxicity of Cationic Lipids and Cationic Polymers in Gene Delivery. J. Controlled Release 114 (1), 100–109. 10.1016/j.jconrel.2006.04.014 Maeda N., Takeuchi Y., Takada M., Sadzuka Y., Namba Y., Oku N. (2004). Anti-neovascular Therapy by Use of Tumor Neovasculature-Targeted Long-Circulating Liposome. J. controlled release 100 (1), 41–52. 10.1016/j.jconrel.2004.07.033 Manconi M., Marongiu F., Castangia I., Manca M. L., Caddeo C., Tuberoso C. I. G., et al. (2016). Polymer-associated Liposomes for the Oral Delivery of Grape Pomace Extract. Colloids Surf. B: biointerfaces 146, 910–917. 10.1016/j.colsurfb.2016.07.043 Mannino R., Lu R. (2018). Cochleates Made with Soy Phosphatidylserine. Google Patents. Mansoori M., Agrawal S., Jawade S., Khan M. (2012). A Review on Liposome. Int. J. Adv. Res. Pharm. Bio-sciences 2 (4), 453–464. Maritim S., Boulas P., Lin Y. (2021). Comprehensive Analysis of Liposome Formulation Parameters and Their Influence on Encapsulation, Stability and Drug Release in Glibenclamide Liposomes. Int. J. Pharmaceutics 592, 120051. 10.1016/j.ijpharm.2020.120051 Marsh D. (2001). Elastic Constants of Polymer-Grafted Lipid Membranes. Biophysical J. 81 (4), 2154–2162. 10.1016/s0006-3495(01)75863-8 Matole V., Shegaonkar A., Kumbhar S., Thorat Y., Hosmani A. (2020). Need of Liposomes as a Novel Drug Delivery System. Res. J. Pharm. Dosage Forms Technology 12 (4), 285–294. 10.5958/0975-4377.2020.00047.6 Matsuoka S., Murata M. (2002). Cholesterol Markedly Reduces Ion Permeability Induced by Membrane-Bound Amphotericin B.. Biochim. Biophys. Acta (Bba) - Biomembranes 1564 (2), 429–434. 10.1016/s0005-2736(02)00491-1 Mehnert W., Mäder K. (2012). Solid Lipid Nanoparticles. Adv. Drug Deliv. Rev. 64, 83–101. 10.1016/j.addr.2012.09.021 Metselaar J. M., Wauben M. H. M., Wagenaar-Hilbers J. P. A., Boerman O. C., Storm G. (2003). Complete Remission of Experimental Arthritis by Joint Targeting of Glucocorticoids with Long-Circulating Liposomes. Arthritis Rheum. 48 (7), 2059–2066. 10.1002/art.11140 Meure L. A., Foster N. R., Dehghani F. (2008). Conventional and Dense Gas Techniques for the Production of Liposomes: a Review. Aaps Pharmscitech 9 (3), 798. 10.1208/s12249-008-9097-x Miao L., Nielsen M., Thewalt J., Ipsen J. H., Bloom M., Zuckermann M. J., et al. (2002). From Lanosterol to Cholesterol: Structural Evolution and Differential Effects on Lipid Bilayers. Biophysical J. 82 (3), 1429–1444. 10.1016/s0006-3495(02)75497-0 Moghimi S. M., Hunter A. C., Murray J. C. (2001). Long-circulating and Target-specific Nanoparticles: Theory to Practice. Pharmacol. Rev. 53 (2), 283–318. Moghimi S. M., Patel H. M. (2002). Modulation of Murine Liver Macrophage Clearance of Liposomes by Diethylstilbestrol. The Effect of Vesicle Surface Charge and a Role for the Complement Receptor Mac-1 (CD11b/CD18) of Newly Recruited Macrophages in Liposome Recognition. J. Control. Release 78 (1-3), 55–65. 10.1016/s0168-3659(01)00481-3 Moghimi S. M., Szebeni J. (2003). Stealth Liposomes and Long Circulating Nanoparticles: Critical Issues in Pharmacokinetics, Opsonization and Protein-Binding Properties. Prog. lipid Res. 42 (6), 463–478. 10.1016/s0163-7827(03)00033-x Montaseri H., Kruger C. A., Abrahamse H. (2020). Review: Organic Nanoparticle Based Active Targeting for Photodynamic Therapy Treatment of Breast Cancer Cells. Oncotarget 11 (22), 2120–2136. 10.18632/oncotarget.27596 Mozafari M. R. (2005). Liposomes: an Overview of Manufacturing Techniques. Cell Mol Biol Lett 10 (4), 711–719. Mozafari M. R., Reed C. J., Rostron C. (2007). Cytotoxicity Evaluation of Anionic Nanoliposomes and Nanolipoplexes Prepared by the Heating Method without Employing Volatile Solvents and Detergents. Pharmazie 62 (3), 205–209. Müller R. H., Mäder K., Gohla S. (2000). Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery - a Review of the State of the Art. Eur. J. Pharm. Biopharm. 50 (1), 161–177. 10.1016/s0939-6411(00)00087-4 Müller R. H., Radtke M., Wissing S. A. (2002). Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) in Cosmetic and Dermatological Preparations. Adv. Drug Deliv. Rev. 54, S131–S155. 10.1016/s0169-409x(02)00118-7 Müller R., Petersen R., Hommoss A., Pardeike J. (2007). Nanostructured Lipid Carriers (NLC) in Cosmetic Dermal Products☆. Adv. Drug Deliv. Rev. 59 (6), 522–530. 10.1016/j.addr.2007.04.012 Nagarajan R. (2002). Molecular Packing Parameter and Surfactant Self-Assembly: The Neglected Role of the Surfactant Tail†. Langmuir 18 (1), 31–38. 10.1021/la010831y Nakanishi T., Hayashi A., Kunisawa J., Tsutsumi Y., Tanaka K., Yashiro-Ohtani Y., et al. (2000). Fusogenic Liposomes Efficiently Deliver Exogenous Antigen through the Cytoplasm into the MHC Class I Processing Pathway. Eur. J. Immunol. 30 (6), 1740–1747. 10.1002/1521-4141(200006)30:6<1740::aid-immu1740>3.0.co;2-u Naskar A., Kim K.-s. (2021). Potential novel food-related and biomedical applications of nanomaterials combined with bacteriocins. Pharmaceutics 13, 86. 10.3390/pharmaceutics13010086 Nasrabadi H. T., Abbasi E., Davaran S., Kouhi M., Akbarzadeh A. (2016). Bimetallic Nanoparticles: Preparation, Properties, and Biomedical Applications. Artif. Cell Nanomedicine, Biotechnol. 44 (1), 376–380. 10.3109/21691401.2014.953632 Nasti T. H., Khan M. A., Owais M. (2006). Enhanced Efficacy of pH-Sensitive Nystatin Liposomes against Cryptococcus Neoformans in Murine Model. J. Antimicrob. Chemother. 57 (2), 349–352. 10.1093/jac/dki454 Noble G. T., Stefanick J. F., Ashley J. D., Kiziltepe T., Bilgicer B. (2014). Ligand-targeted Liposome Design: Challenges and Fundamental Considerations. Trends Biotechnology 32 (1), 32–45. 10.1016/j.tibtech.2013.09.007 North S., Butts C. (2005). Vaccination with BLP25 Liposome Vaccine to Treat Non-small Cell Lung and Prostate Cancers. Expert Rev. Vaccin. 4 (3), 249–257. 10.1586/14760584.4.3.249 Nunes S. S., Fernandes R. S., Cavalcante C. H., da Costa César I., Leite E. A., Lopes S. C. A., et al. (2019). Influence of PEG Coating on the Biodistribution and Tumor Accumulation of pH-Sensitive Liposomes. Drug Deliv. Transl. Res. 9 (1), 123–130. 10.1007/s13346-018-0583-8 Ohvo-Rekilà H., Ramstedt B., Leppimäki P., Slotte J. P. (2002). Cholesterol Interactions with Phospholipids in Membranes. Prog. lipid Res. 41 (1), 66–97. 10.1016/s0163-7827(01)00020-0 Okamoto Y., Masum S. M., Miyazawa H., Yamazaki M. (2008). Low-pH-induced Transformation of Bilayer Membrane into Bicontinuous Cubic Phase in Dioleoylphosphatidylserine/monoolein Membranes. Langmuir 24 (7), 3400–3406. 10.1021/la7036795 Otake K., Imura T., Sakai H., Abe M. (2001). Development of a New Preparation Method of Liposomes Using Supercritical Carbon Dioxide. langmuir 17 (13), 3898–3901. 10.1021/la010122k Pan L. G., Tomás M. C., Añón M. C. (2002). Effect of sunflower Lecithins on the Stability of Water-In-Oil and Oil-In-Water Emulsions. J. Surfact Deterg 5 (2), 135–143. 10.1007/s11743-002-0213-1 Panahi Y., Farshbaf M., Mohammadhosseini M., Mirahadi M., Khalilov R., Saghfi S., et al. (2017). Recent Advances on Liposomal Nanoparticles: Synthesis, Characterization and Biomedical Applications. Artif. Cell Nanomedicine, Biotechnol. 45 (4), 788–799. 10.1080/21691401.2017.1282496 Papagiannaros A., Hatziantoniou S., Dimas K., Papaioannou G. T., Demetzos C. (2006). A Liposomal Formulation of Doxorubicin, Composed of Hexadecylphosphocholine (HePC): Physicochemical Characterization and Cytotoxic Activity against Human Cancer Cell Lines. Biomed. Pharmacother. 60 (1), 36–42. 10.1016/j.biopha.2005.09.001 Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., et al. (2003). Vascular Damage and Anti-angiogenic Effects of Tumor Vessel-Targeted Liposomal Chemotherapy. Cancer Res. 63 (21), 7400–7409. Patel N., Panda S. (2012). Liposome Drug Delivery System: a Critic Review. JPSBR 2 (4), 169–175. Pavelić Z., Skalko-Basnet N., Jalsenjak I. (2005). Characterisation and In Vitro Evaluation of Bioadhesive Liposome Gels for Local Therapy of Vaginitis. Int. J. Pharm. 301 (1-2), 140–148. 10.1016/j.ijpharm.2005.05.022 Pawar A., Bothiraja C., Shaikh K., Mali A. (2015). An Insight into Cochleates, a Potential Drug Delivery System. RSC Adv. 5 (99), 81188–81202. 10.1039/c5ra08550k Pawar H. A., Bhangale B. D. (2015). Phytosome as a Novel Biomedicine: a Microencapsulated Drug Delivery System. J. Bioanal. Biomed. 7 (1), 6–12. Peravali R., Brock R., Bright E., Mills P., Petty D., Alberts J. (2014). Enhancing the Enhanced Recovery Program in Colorectal Surgery - Use of Extended-Release Epidural Morphine (DepoDur). Ann. Coloproctol. 30 (4), 186. 10.3393/ac.2014.30.4.186 Phuphanich S., Maria B., Braeckman R., Chamberlain M. (2007). A Pharmacokinetic Study of Intra-CSF Administered Encapsulated Cytarabine (DepoCyt) for the Treatment of Neoplastic Meningitis in Patients with Leukemia, Lymphoma, or Solid Tumors as Part of a Phase III Study. J. Neurooncol. 81 (2), 201–208. 10.1007/s11060-006-9218-x Pinilla C. M. B., Reque P. M., Brandelli A. (2020). Effect of Oleic Acid, Cholesterol, and Octadecylamine on Membrane Stability of Freeze-Dried Liposomes Encapsulating Natural Antimicrobials. Food Bioproc. Technol 13 (4), 599–610. 10.1007/s11947-020-02419-8 Portet T., Dimova R. (2010). A New Method for Measuring Edge Tensions and Stability of Lipid Bilayers: Effect of Membrane Composition. Biophysical J. 99 (10), 3264–3273. 10.1016/j.bpj.2010.09.032 Portilla S., Fernández L., Gutiérrez D., Rodríguez A., García P. (2020). Encapsulation of the Antistaphylococcal Endolysin LysRODI in pH-Sensitive Liposomes. Antibiotics 9 (5), 242. 10.3390/antibiotics9050242 Pradhan B., Kumar N., Saha S., Roy A. (2015). Liposome: Method of Preparation, Advantages, Evaluation and its Application. J. Appl. Pharm. Res. 3 (3), 01–08. Puras G., Mashal M., Zárate J., Agirre M., Ojeda E., Grijalvo S., et al. (2014). A Novel Cationic Niosome Formulation for Gene Delivery to the Retina. J. Controlled Release 174, 27–36. 10.1016/j.jconrel.2013.11.004 Qiang L., Yi J., Fu-De C. (2004). Melanoma Vaccine Based on the Vector of Membrane Fusogenic Liposomes. Pharmazie 59 (4), 263–267. Qiao C., Liu J., Yang J., Li Y., Weng J., Shao Y., et al. (2016). Enhanced Non-inflammasome Mediated Immune Responses by Mannosylated Zwitterionic-Based Cationic Liposomes for HIV DNA Vaccines. Biomaterials 85, 1–17. 10.1016/j.biomaterials.2016.01.054 Radwan Almofti M., Harashima H., Shinohara Y., Almofti A., Baba Y., Kiwada H. (2003). Cationic Liposome-Mediated Gene Delivery: Biophysical Study and Mechanism of Internalization. Arch. Biochem. Biophys. 410 (2), 246–253. 10.1016/s0003-9861(02)00725-7 Rahdar A., Sayyadi K., Sayyadi J., Yaghobi Z. (2019). Nano-gels: A Versatile Nano-Carrier Platform for Drug Delivery Systems: A Mini Review. Nanomedicine Res. J. 4 (1), 1–9. Réthoré G., Montier T., Le Gall T., Delepine P., Cammas-Marion S., Lemiègre L., et al. (2007). Archaeosomes Based on Synthetic Tetraether-like Lipids as Novel Versatile Gene Delivery Systems. Chem. Commun. 20, 2054–2056. 10.1039/b618568a() Ricci M., Oliva R., Del Vecchio P., Paolantoni M., Morresi A., Sassi P. (2016). DMSO-induced Perturbation of Thermotropic Properties of Cholesterol-Containing DPPC Liposomes. Biochim. Biophys. Acta (Bba) - Biomembranes 1858 (12), 3024–3031. 10.1016/j.bbamem.2016.09.012 Rizvi I., Nath S., Obaid G., Ruhi M. K., Moore K., Bano S., et al. (2019). A Combination of Visudyne and a Lipid-Anchored Liposomal Formulation of Benzoporphyrin Derivative Enhances Photodynamic Therapy Efficacy in a 3D Model for Ovarian Cancer. Photochem. Photobiol. 95 (1), 419–429. 10.1111/php.13066 Rosenkrands I., Agger E. M., Olsen A. W., Korsholm K. S., Andersen C. S., Jensen K. T., et al. (2005). Cationic Liposomes Containing Mycobacterial Lipids: a New Powerful Th1 Adjuvant System. Infect. Immun. 73 (9), 5817–5826. 10.1128/iai.73.9.5817-5826.2005 Rovira-Bru M., Thompson D. H., Szleifer I. (2002). Size and Structure of Spontaneously Forming Liposomes in lipid/PEG-Lipid Mixtures. Biophysical J. 83 (5), 2419–2439. 10.1016/s0006-3495(02)75255-7 Raj S., Khurana S., Choudhari R., Kesari K. K., Kamal M. A., Garg N., et al. (Editors) (2021). Specific Targeting Cancer Cells with Nanoparticles and Drug Delivery in Cancer Therapy. Seminars in Cancer Biology (Elsevier; ).Saadat E., Amini M., Khoshayand M. R., Dinarvand R., Dorkoosh F. A. (2014). Synthesis and Optimization of a Novel Polymeric Micelle Based on Hyaluronic Acid and Phospholipids for Delivery of Paclitaxel, In Vitro and In-Vivo Evaluation. Int. J. Pharm. 475 (1-2), 163–173. 10.1016/j.ijpharm.2014.08.030 Sahoo S. K., Labhasetwar V. (2003). Nanotech Approaches to Drug Delivery and Imaging. Drug Discov. Today 8 (24), 1112–1120. 10.1016/s1359-6446(03)02903-9 Saliba A.-E., Vonkova I., Deghou S., Ceschia S., Tischer C., Kugler K. G., et al. (2016). A Protocol for the Systematic and Quantitative Measurement of Protein-Lipid Interactions Using the Liposome-Microarray-Based Assay. Nat. Protoc. 11 (6), 1021–1038. 10.1038/nprot.2016.059 Samuni A. M., Lipman A., Barenholz Y. (2000). Damage to Liposomal Lipids: protection by Antioxidants and Cholesterol-Mediated Dehydration. Chem. Phys. Lipids 105 (2), 121–134. 10.1016/s0009-3084(99)00136-x Sankhyan A., Pawar P. (2012). Recent Trends in Niosome as Vesicular Drug Delivery System. J. Appl. Pharm. Sci. 2 (6), 20–32. Santos H. d. L., Lopes M. L., Maggio B., Ciancaglini P. (2005). Na,K-ATPase Reconstituted in Liposomes: Effects of Lipid Composition on Hydrolytic Activity and Enzyme Orientation. Colloids Surf. B: Biointerfaces 41 (4), 239–248. 10.1016/j.colsurfb.2004.12.013 Scheffer L., Solomonov I., Jan Weygand M., Kjaer K., Leiserowitz L., Addadi L. (2005). Structure of Cholesterol/ceramide Monolayer Mixtures: Implications to the Molecular Organization of Lipid Rafts. Biophysical J. 88 (5), 3381–3391. 10.1529/biophysj.104.051870 Scott M. J., Jones M. N. (2001). The Interaction of Phospholipid Liposomes with Zinc Citrate Particles: a Microcalorimetric Investigation. Colloids and Surfaces A:. Physicochemical Eng. Aspects 182 (1-3), 247–256. 10.1016/s0927-7757(00)00827-x Scrimgeour C., Gao Y., Oh W. Y., Shahidi F. (2005). Chemistry of Fatty Acids. Bailey's Ind. oil fat Prod., 1–40. 10.1002/047167849x.bio005 Semple S. C., Leone R., Wang J., Leng E. C., Klimuk S. K., Eisenhardt M. L., et al. (2005). Optimization and Characterization of a Sphingomyelin/cholesterol Liposome Formulation of Vinorelbine with Promising Antitumor Activity. J. Pharm. Sci. 94 (5), 1024–1038. 10.1002/jps.20332 Seo J. W., Qin S., Mahakian L. M., Watson K. D., Kheirolomoom A., Ferrara K. W. (2011). Positron Emission Tomography Imaging of the Stability of Cu-64 Labeled Dipalmitoyl and Distearoyl Lipids in Liposomes. J. controlled release 151 (1), 28–34. 10.1016/j.jconrel.2011.01.008 Shah K. A., Date A. A., Joshi M. D., Patravale V. B. (2007). Solid Lipid Nanoparticles (SLN) of Tretinoin: Potential in Topical Delivery. Int. J. Pharm. 345 (1-2), 163–171. 10.1016/j.ijpharm.2007.05.061 Shehata T., Ogawara K., Higaki K., Kimura T. (2008). Prolongation of Residence Time of Liposome by Surface-Modification with Mixture of Hydrophilic Polymers. Int. J. Pharm. 359 (1-2), 272–279. 10.1016/j.ijpharm.2008.04.004 Shim G., Han S.-E., Yu Y.-H., Lee S., Lee H. Y., Kim K., et al. (2011). Trilysinoyl Oleylamide-Based Cationic Liposomes for Systemic Co-delivery of siRNA and an Anticancer Drug. J. controlled release 155 (1), 60–66. 10.1016/j.jconrel.2010.10.017 Shim G., Kim M.-G., Park J. Y., Oh Y.-K. (2013). Application of Cationic Liposomes for Delivery of Nucleic Acids. Asian J. Pharm. Sci. 8 (2), 72–80. 10.1016/j.ajps.2013.07.009 Shoji J. i., Tanihara Y., Uchiyama T., Kawai A. (2004). Preparation of Virosomes Coated with the Vesicular Stomatitis Virus Glycoprotein as Efficient Gene Transfer Vehicles for Animal Cells. Microbiol. Immunol. 48 (3), 163–174. 10.1111/j.1348-0421.2004.tb03502.x Shrivastava S., Lole K. S., Tripathy A. S., Shaligram U. S., Arankalle V. A. (2009). Development of Candidate Combination Vaccine for Hepatitis E and Hepatitis B: a Liposome Encapsulation Approach. Vaccine 27 (47), 6582–6588. 10.1016/j.vaccine.2009.08.033 Silindir M., Erdoğan S., Özer A. Y., Doğan A. L., Tuncel M., Uğur Ö., et al. (2013). Nanosized Multifunctional Liposomes for Tumor Diagnosis and Molecular Imaging by SPECT/CT. J. Liposome Res. 23 (1), 20–27. 10.3109/08982104.2012.722107 Silva C., Aranda F. J., Ortiz A., Martínez V., Carvajal M., Teruel J. A. (2011). Molecular Aspects of the Interaction between Plants Sterols and DPPC Bilayers. J. Colloid Interf. Sci. 358 (1), 192–201. 10.1016/j.jcis.2011.02.048 Silverman J. A., Reynolds L., Deitcher S. R. (2013). Pharmacokinetics and Pharmacodynamics of Vincristine Sulfate Liposome Injection (VSLI) in Adults with Acute Lymphoblastic Leukemia. J. Clin. Pharmacol. 53 (11), 1139–1145. 10.1002/jcph.155 Silverman J. A., Deitcher S. R. (2013). Marqibo (Vincristine Sulfate Liposome Injection) Improves the Pharmacokinetics and Pharmacodynamics of Vincristine. Cancer Chemother. Pharmacol. 71 (3), 555–564. 10.1007/s00280-012-2042-4 Simões S., Moreira J. N., Fonseca C., Düzgüneş N., de Lima M. C. P. (2004). On the Formulation of pH-Sensitive Liposomes with Long Circulation Times. Adv. Drug Deliv. Rev. 56 (7), 947–965. 10.1016/j.addr.2003.10.038 Singh D., Dilnawaz F., Sahoo S. K. (2020). Challenges of Moving Theranostic Nanomedicine into the Clinic. Future Med. 10.2217/nnm-2019-0401 Sioud M., Sørensen D. R. (2003). Cationic Liposome-Mediated Delivery of siRNAs in Adult Mice. Biochem. biophysical Res. Commun. 312 (4), 1220–1225. 10.1016/j.bbrc.2003.11.057 Socaciu C., Jessel R., Diehl H. A. (2000). Competitive Carotenoid and Cholesterol Incorporation into Liposomes: Effects on Membrane Phase Transition, Fluidity, Polarity and Anisotropy. Chem. Phys. Lipids 106 (1), 79–88. 10.1016/s0009-3084(00)00135-3 Sodt A. J., Pastor R. W., Lyman E. (2015). Hexagonal Substructure and Hydrogen Bonding in Liquid-Ordered Phases Containing Palmitoyl Sphingomyelin. Biophysical J. 109 (5), 948–955. 10.1016/j.bpj.2015.07.036 Sugita T., Yoshikawa T., Gao J.-Q., Shimokawa M., Oda A., Niwa T., et al. (2005). Fusogenic Liposome Can Be Used as an Effective Vaccine Carrier for Peptide Vaccination to Induce Cytotoxic T Lymphocyte (CTL) Response. Biol. Pharm. Bull. 28 (1), 192–193. 10.1248/bpb.28.192 Suk J. S., Xu Q., Kim N., Hanes J., Ensign L. M. (2016). PEGylation as a Strategy for Improving Nanoparticle-Based Drug and Gene Delivery. Adv. Drug Deliv. Rev. 99 (Pt A), 28–51. 10.1016/j.addr.2015.09.012 Sun M., Northup N., Marga F., Huber T., Byfield F. J., Levitan I., et al. (2007). The Effect of Cellular Cholesterol on Membrane-Cytoskeleton Adhesion. J. Cel. Sci. 120 (13), 2223–2231. 10.1242/jcs.001370 Tabatabaei Mirakabad F. S., Akbarzadeh A., Milani M., Zarghami N., Taheri-Anganeh M., Zeighamian V., et al. (2016). A Comparison between the Cytotoxic Effects of Pure Curcumin and Curcumin-Loaded PLGA-PEG Nanoparticles on the MCF-7 Human Breast Cancer Cell Line. Artif. Cell Nanomedicine, Biotechnol. 44 (1), 423–430. 10.3109/21691401.2014.955108 Tan C., Feng B., Zhang X., Xia W., Xia S. (2016). Biopolymer-coated Liposomes by Electrostatic Adsorption of Chitosan (Chitosomes) as Novel Delivery Systems for Carotenoids. Food hydrocolloids 52, 774–784. 10.1016/j.foodhyd.2015.08.016 Thompson A. K., Haisman D., Singh H. (2006). Physical Stability of Liposomes Prepared from Milk Fat Globule Membrane and Soya Phospholipids. J. Agric. Food Chem. 54 (17), 6390–6397. 10.1021/jf0605695 Toh M.-R., Chiu G. N. C. (2013). Liposomes as Sterile Preparations and Limitations of Sterilisation Techniques in Liposomal Manufacturing. Asian J. Pharm. Sci. 8 (2), 88–95. 10.1016/j.ajps.2013.07.011 Torchilin V. P. (2006). Recent Approaches to Intracellular Delivery of Drugs and DNA and Organelle Targeting. Annu. Rev. Biomed. Eng. 8, 343–375. 10.1146/annurev.bioeng.8.061505.095735 Trandum C., Westh P., Jørgensen K., Mouritsen O. G. (2000). A Thermodynamic Study of the Effects of Cholesterol on the Interaction between Liposomes and Ethanol. Biophysical J. 78 (5), 2486–2492. 10.1016/s0006-3495(00)76793-2 Trucillo P., Campardelli R., Reverchon E. (2020). Liposomes: From Bangham to Supercritical Fluids. Processes 8 (9), 1022. 10.3390/pr8091022 Trucillo P., Campardelli R., Reverchon E. (2017). Supercritical CO 2 Assisted Liposomes Formation: Optimization of the Lipidic Layer for an Efficient Hydrophilic Drug Loading. J. Co2 utilization 18, 181–188. 10.1016/j.jcou.2017.02.001 Tzogani K., Penttilä K., Lapveteläinen T., Hemmings R., Koenig J., Freire J., et al. (2020). EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes. Oncologist 25 (9), e1414–e20. 10.1634/theoncologist.2019-0785 Ulrich A. S. (2002). Biophysical Aspects of Using Liposomes as Delivery Vehicles. Biosci. Rep. 22 (2), 129–150. 10.1023/a:1020178304031 Vakili-Ghartavol R., Rezayat S. M., Faridi-Majidi R., Sadri K., Jaafari M. R. (2020). Optimization of Docetaxel Loading Conditions in Liposomes: Proposing Potential Products for Metastatic Breast Carcinoma Chemotherapy. Sci. Rep. 10 (1), 5569. 10.1038/s41598-020-62501-1 Van Slooten M. L., Storm G., Zoephel A., Küpcü Z., Boerman O., Crommelin D. J. A., et al. (2000). Liposomes Containing Interferon-Gamma as Adjuvant in Tumor Cell Vaccines. Pharm. Res. 17 (1), 42–48. 10.1023/a:1007514424253 Varypataki E. M., Benne N., Bouwstra J., Jiskoot W., Ossendorp F. (2017). Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines. Cancer Immunol. Res. 5 (3), 222–233. 10.1158/2326-6066.cir-16-0283 Veneti E., Tu R. S., Auguste D. T. (2016). RGD-targeted Liposome Binding and Uptake on Breast Cancer Cells Is Dependent on Elastin Linker Secondary Structure. Bioconjug. Chem. 27 (8), 1813–1821. 10.1021/acs.bioconjchem.6b00205 Wagner A., Platzgummer M., Kreismayr G., Quendler H., Stiegler G., Ferko B., et al. (2006). GMP Production of Liposomes-A New Industrial Approach. J. liposome Res. 16 (3), 311–319. 10.1080/08982100600851086 Walde P., Ichikawa S. (2001). Enzymes inside Lipid Vesicles: Preparation, Reactivity and Applications. Biomol. Eng. 18 (4), 143–177. 10.1016/s1389-0344(01)00088-0 Wang Y., Tu S., Li R., Yang X., Liu L., Zhang Q. (2010). Cholesterol Succinyl Chitosan Anchored Liposomes: Preparation, Characterization, Physical Stability, and Drug Release Behavior. Nanomedicine: Nanotechnology, Biol. Med. 6 (3), 471–477. 10.1016/j.nano.2009.09.005 Wang Y., Wang S., Firempong C. K., Zhang H., Wang M., Zhang Y., et al. (2017). Enhanced Solubility and Bioavailability of Naringenin via Liposomal Nanoformulation: Preparation and In Vitro and In Vivo Evaluations. Aaps Pharmscitech 18 (3), 586–594. 10.1208/s12249-016-0537-8 Weissig V. (2015). DQAsomes as the Prototype of Mitochondria-Targeted Pharmaceutical Nanocarriers: Preparation, Characterization, and Use. Mitochondrial Med. Springer, 1–11. 10.1007/978-1-4939-2288-8_1 Weng C.-S., Wu C.-C., Chen T.-C., Chen J.-R., Huang C.-Y., Chang C.-L. (2019). Retrospective Analysis of Comparative Outcomes in Recurrent Platinum-Sensitive Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin (Lipo-Dox) and Carboplatin versus Paclitaxel and Carboplatin. Cmar 11, 9899–9905. 10.2147/cmar.s217329 Wibroe P. P., Ahmadvand D., Oghabian M. A., Yaghmur A., Moghimi S. M. (2016). An Integrated Assessment of Morphology, Size, and Complement Activation of the PEGylated Liposomal Doxorubicin Products Doxil, Caelyx, DOXOrubicin, and SinaDoxosome. J. Controlled Release 221, 1–8. 10.1016/j.jconrel.2015.11.021 Wong J. P., Nagata L. P., Dale R. M. (2001). Liposome-encapsulated Nucleic Acid-Based Drugs and Vaccines as Novel Antiviral Agents. Recent Dev. Antivir. Res., 175–191. Wu R. G., Dai J. D., Wu F. G., Zhang X. H., Li W. H., Wang Y. R. (2012). Competitive Molecular Interaction Among Paeonol-Loaded Liposomes: Differential Scanning Calorimetry and Synchrotron X-ray Diffraction Studies. Int. J. Pharm. 438 (1-2), 91–97. 10.1016/j.ijpharm.2012.08.052 Wu X., Dai X., Liao Y., Sheng M., Shi X. (2021). Investigation on Drug Entrapment Location in Liposomes and Transfersomes Based on Molecular Dynamics Simulation. J. Mol. Model. 27 (4), 1–10. 10.1007/s00894-021-04722-3 Xia S., Xu S. (2005). Ferrous Sulfate Liposomes: Preparation, Stability and Application in Fluid Milk. Food Res. Int. 38 (3), 289–296. 10.1016/j.foodres.2004.04.010 Xu Q., Tanaka Y., Czernuszka J. T. (2007). Encapsulation and Release of a Hydrophobic Drug from Hydroxyapatite Coated Liposomes. Biomaterials 28 (16), 2687–2694. 10.1016/j.biomaterials.2007.02.007 Xu X., Khan M. A., Burgess D. J. (2011). A Quality by Design (QbD) Case Study on Liposomes Containing Hydrophilic API: I. Formulation, Processing Design and Risk Assessment. Int. J. Pharm. 419 (1-2), 52–59. 10.1016/j.ijpharm.2011.07.012 Yamauchi M., Tsutsumi K., Abe M., Uosaki Y., Nakakura M., Aoki N. (2007). Release of Drugs from Liposomes Varies with Particle Size. Biol. Pharm. Bull. 30 (5), 963–966. 10.1248/bpb.30.963 Yang T., Cui F.-D., Choi M.-K., Lin H., Chung S.-J., Shim C.-K., et al. (2007). Liposome Formulation of Paclitaxel with Enhanced Solubility and Stability. Drug Deliv. 14 (5), 301–308. 10.1080/10717540601098799 Yang Z.-Z., Li J.-Q., Wang Z.-Z., Dong D.-W., Qi X.-R. (2014). Tumor-targeting Dual Peptides-Modified Cationic Liposomes for Delivery of siRNA and Docetaxel to Gliomas. Biomaterials 35 (19), 5226–5239. 10.1016/j.biomaterials.2014.03.017 Yavlovich A., Singh A., Tarasov S., Capala J., Blumenthal R., Puri A. (2009). Design of Liposomes Containing Photopolymerizable Phospholipids for Triggered Release of Contents. J. Therm. Anal. Calorim. 98 (1), 97–104. 10.1007/s10973-009-0228-8 Yoshida I., Saito A. M., Tanaka S., Choi I., Hidaka M., Miyata Y., et al. (2020). Intravenous Itraconazole Compared with Liposomal Amphotericin B as Empirical Antifungal Therapy in Patients with Neutropaenia and Persistent Fever. Mycoses 63 (8), 794–801. 10.1111/myc.13100 Yoshikawa T., Imazu S., Gao J.-Q., Hayashi K., Tsuda Y., Okada N., et al. (2006). Non-methylated CpG Motif Packaged into Fusogenic Liposomes Enhance Antigen-specific Immunity in Mice. Biol. Pharm. Bull. 29 (1), 105–109. 10.1248/bpb.29.105 Yoshikawa T., Okada N., Tsujino M., Gao J.-Q., Hayashi A., Tsutsumi Y., et al. (2006). Vaccine Efficacy of Fusogenic Liposomes Containing Tumor Cell-Lysate against Murine B16BL6 Melanoma. Biol. Pharm. Bull. 29 (1), 100–104. 10.1248/bpb.29.100 Yu F., Tang X. (2016). Novel Long-Circulating Liposomes Consisting of PEG Modified β-Sitosterol for Gambogic Acid Delivery. j nanosci nanotechnol 16 (3), 3115–3121. 10.1166/jnn.2016.12405 Yu J. Y., Chuesiang P., Shin G. H., Park H. J. (2021). Post-processing Techniques for the Improvement of Liposome Stability. Pharmaceutics 13 (7), 1023. 10.3390/pharmaceutics13071023 Yu T., Ji P., Zhao W. M. (2015). Preparation of Baicalein Liposome-Lyophilized Powder and its Pharmacokinetics Study. Zhong Yao Cai 38 (11), 2404–2407. Yuba E. (2020). Development of Functional Liposomes by Modification of Stimuli-Responsive Materials and Their Biomedical Applications. J. Mater. Chem. B 8 (6), 1093–1107. 10.1039/c9tb02470k Yuba E., Kanda Y., Yoshizaki Y., Teranishi R., Harada A., Sugiura K., et al. (2015). pH-sensitive Polymer-Liposome-Based Antigen Delivery Systems Potentiated with Interferon-γ Gene Lipoplex for Efficient Cancer Immunotherapy. Biomaterials 67, 214–224. 10.1016/j.biomaterials.2015.07.031 Zaru M., Mourtas S., Klepetsanis P., Fadda A. M., Antimisiaris S. G. (2007). Liposomes for Drug Delivery to the Lungs by Nebulization. Eur. J. Pharmaceutics Biopharmaceutics 67 (3), 655–666. 10.1016/j.ejpb.2007.04.005 Zhang J., Chen Y., Li X., Liang X., Luo X. (2016). The Influence of Different Long-Circulating Materials on the Pharmacokinetics of Liposomal Vincristine Sulfate. Int. J. Nanomedicine 11, 4187–4197. 10.2147/IJN.S109547 Zhang J., Tian H., Li C., Cheng L., Zhang S., Zhang X., et al. (2013). Antitumor Effects Obtained by Autologous Lewis Lung Cancer Cell Vaccine Engineered to Secrete Mouse Interleukin 27 by Means of Cationic Liposome. Mol. Immunol. 55 (3-4), 264–274. 10.1016/j.molimm.2013.02.006 Zhang J. A., Pawelchak J. (2000). Effect of pH, Ionic Strength and Oxygen burden on the Chemical Stability of EPC/cholesterol Liposomes under Accelerated Conditions. Part 1: Lipid Hydrolysis. Eur. J. Pharm. Biopharm. 50 (3), 357–364. 10.1016/s0939-6411(00)00127-2 Zhao L., Temelli F., Curtis J. M., Chen L. (2015). Preparation of Liposomes Using Supercritical Carbon Dioxide Technology: Effects of Phospholipids and Sterols. Food Res. Int. 77, 63–72. 10.1016/j.foodres.2015.07.006 Zhao X. B., Muthusamy N., Byrd J. C., Lee R. J. (2007). Cholesterol as a Bilayer Anchor for PEGylation and Targeting Ligand in Folate‐receptor‐targeted Liposomes. J. Pharm. Sci. 96 (9), 2424–2435. 10.1002/jps.20885 Zhao Y.-Z., Liang H.-D., Mei X.-G., Halliwell M. (2005). Preparation, Characterization and In Vivo Observation of Phospholipid-Based Gas-Filled Microbubbles Containing Hirudin. Ultrasound Med. Biol. 31 (9), 1237–1243. 10.1016/j.ultrasmedbio.2005.05.007 Zhu R., Wang Z., Liang P., He X., Zhuang X., Huang R., et al. (2017). Efficient VEGF Targeting Delivery of DOX Using Bevacizumab Conjugated SiO2@LDH for Anti-neuroblastoma Therapy. Acta Biomater. 63, 163–180. 10.1016/j.actbio.2017.09.009 Zupančič Š., Kocbek P., Zariwala M. G., Renshaw D., Gul M. O., Elsaid Z., et al. (2014). Design and Development of Novel Mitochondrial Targeted Nanocarriers, DQAsomes for Curcumin Inhalation. Mol. Pharm. 11 (7), 2334–2345. 10.1021/mp500003q